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ABSTRACT
An Investigation into Formulation and Therapeutic Effectiveness of Nanoparticle Drug Delivery for
Select Pharmaceutical Agents
by
Dustin Lynn Cooper
Drug based nanoparticle (NP) formulations have gained considerable attention over the past decade for
their use in various drug delivery systems. NPs have been shown to increase bioavailability, decrease
side effects of highly toxic drugs, and prolong drug release. Furthermore, polymer based, biodegradable
nanodelivery has become increasing popular in the field of NP formulation because of their high degree
of compatibility and low rate of toxicity.

Due to their popularity, commercially available polymers such as poly lactic acid (PLA), poly glycolic
acid (PGA) and polylactic-co-glycolic acid (PLGA) are commonly used in the development and design
of new nano based delivery systems. Nonsteriodal anti-inflammatory drugs (NSAIDs) are commonly
used for the treatment of pain and inflammation. NSAIDs such as diclofenac and celecoxib function by
blocking cyclooxygenase expression and reducing prostaglandin synthesis. Unfortunately, the
pharmacological actions of NSAIDs can lead to the development of several adverse side effects such as
gastrointestinal ulceration and bleeding.

The aim of this study was to formulate and optimize diclofenac or celecoxib entrapped polymer NPs
using an emulsion-diffusion-evaporation technique. NP formulations were evaluated based on specific
formula parameters such as particle size, zeta potential, morphology, and entrapment efficiency. Effects
of stabilizer type, stabilizer concentration, centrifugal force, drug amount, and/or emulsifier (lecithin) on
nanoparticle characterization were examined for formula optimization.

Results of the formulation studies showed that NPs developed using polylactide-co-glycolide (PLGA)
polymers and the stabilizer didodecyldimethylammonium bromide (DMAB) demonstrated enhanced
stability, drug entrapment, and reduced particle size. These findings demonstrate an effective method for
polymer NP formulation of diclofenac or celecoxib. Furthermore, the results reported herein support a
novel method of drug delivery that may function to reduce known adverse effects of these
pharmacotherapeutic agents.
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CHAPTER 1
INTRODUCTION
Nanoparticles (NPs) are solid colloidal particles ranging in size from 10 to 1000 nm and contain
nanomolecular materials, in which active ingredients are dissolved, entrapped, or encapsulated (1 - 3).
NPs are currently gaining popularity in the medical field as an effective means of drug delivery and
therapy (Shive and Anderson 1997; Buzea et al 2007; De Jong, and Borm 2008; Cooper and
Harirforoosh 2014). Through the use of colloidal based NPs, researchers are effectively creating a drug
delivery system that can improve a drug’s overall kinetics, dynamics, and targeted release (Cooper et al
2014). Altered drug formulation designs using NP encapsulated drugs offer a safe and effective
alternative in pharmacotherapy. New NP formulations have been found to be well suited for a variety of
drugs in the biomedical field by offering a higher degree of safety and drug efficacy with regard to
disease treatment and the onset of drug associated adverse side effects (Shive and Anderson 1997;
Doane and Burda 2012; Cooper et al 2014). Drug loaded NPs have been shown to increase the
therapeutic indices of entrapped agents and reduce development of adverse side effects (Shive and
Anderson 1997; Uchino et al. 2005; Desai et al. 2008; Li et al. 2011; Vishnu and Roy 2011; Doane and
Burda 2012; Cooper et al 2014). Recent studies on chemotherapeutic and antibiotic NP encapsulated
drugs have shown potential in accelerating disease treatment and reducing associated adverse
complications (Mizumura et al 2001; Uchino et al 2005; Li et al 2011; Vishnu and Roy 2011; Benival
and Devarajan 2012; Jain et al 2012; Zhao et al 2013; Cooper et al 2014).
Pharmaceutical agents such as nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used
among the general population (Cooper et al 2014). NSAIDs act to block the formation of the
inflammatory messenger molecule prostaglandin by inhibiting the cyclooxygenase (COX) enzyme
(Simmons 2004; Brater 2006; Dogne 2006; Cooper et al 2014). The most commonly reported side
effects of these drugs are gastrointestinal ulcerations, dyspepsia, and diarrhea. Certain cardiovascular
side effects such as stroke and myocardial infarction are also common among COX-2-selected inhibitors
8

such as rofecoxib and celecoxib (Goldberg 1999; Simmons et al 2004; Caldwell et al 2006; Dogne et al
2006).
Evidence suggest that the use of NPs in drug delivery may effectively reduce complications
associated with the use of NSAIDs (Mizumura et al 2001; Uchino et al 2005; Desai 2008; Li et al 2011;
Vishnu and Roy 2011; Benival and Devarajan 2012; Jain et al 2012; Zhao et al 2013; Cooper et al
2014). In the literature, drug reformulation studies using polymer based NPs have shown positive
benefits in regards to drug induced complications as well as reductions in associated adverse events.
When applied towards the commonality of NSAID use, and the known efficacy and side effects
associated with such drugs, investigation into NP reformulation of these pharmaceutical agents was
warranted.
Currently, there are many types of polymers available for polymer based NP formulation. Examples
of common polymers employed in NP formulation are poly (lactic acid) (PLA), poly (glycolic acid)
(PGA), and poly (lactic-co-glycolic acid) (PLGA) (Cooper et al 2014). Like many NP delivery systems,
polymer based NP formulation can act to offset drug release by desorption of bound drug from particle
surfaces, erosion of the polymer membrane, and/or drug diffusion (Buzea et al 2007; Dejong and Borm
2008; Cooper et al 2014). The three aforementioned stages at which polymer NPs can release active
pharmaceutical agents makes them an ideal choice in attempting to formulate a new and novel drug
delivery systems that could act to modify or control drug release and offset the occurrence of drug
related adverse events.
In regards to polymer choice, PLA has been shown to exhibit a prolonged rate of degradation and
drug release (Cooper et al 2014). In counter to PLA characteristics, PGA is commonly used in
formulations were fast hydrolysis and erosion are warranted. As such, in this study focused was placed
on the use of PLGA because of its known intermediate rate of hydrolysis and biodegradation in
comparison to PLA or PGA. Furthermore, polymeric NP formulations consisting of PLGA can result in
minimal or reduced toxicity due to product conversion to the Krebs cycle intermediates lactic acid and
9

glycolic acid. Because of these favorable characteristics, PLGA was chosen as the primary polymer to
be used.
Solvent evaporation is one of the more commonly used formulation techniques for production of
polymer based NPs (Savjani et al 2012; Cooper et al 2014, Cooper and Hariroforoosh 2014; Cooper and
Harirforoosh 2014). In this study polymer encapsulated pharmaceutical agents were formulated using a
previously described oil in water solvent evaporation technique Cooper and Hariroforoosh 2014; Cooper
and Harirforoosh 2014). To facilitate NP formulation, an organic phase consisting of polymer and drug
dissolved in ethyl acetate was added to an aqueous phase containing a stabilizer. Ethyl acetate has been
shown to be effective in the formulation and creation of drug loaded NP delivery systems and was thus
chosen as the primary solvent for these formulation studies. The stabilizer didodecydimethylammonium
bromide (DMAB) is highly effective at creating positively charged particles (Cooper and Hariroforoosh
2014). In DMAB based formulation studies, these positively charged surface characteristics have been
shown to impede particle agglomeration and enhance system stability, making them an ideal stabilizer of
choice for new NP formulation analysis (Cooper and Hariroforoosh 2014; Cooper and Harirforoosh
2014). A second stabilizer, poly vinyl alcohol (PVA), was also chosen as a comparison model for
stabilizer effects in NP formulation. PVA has been extensively used in various formulation designs. Due
to PVA’s extensive history in drug delivery and formulation, it was chosen for comparative stabilizer
analysis during formula optimization techniques.
The overall aim of this research was to formulate, develop and optimize a polymeric NP loaded
drug delivery system. The results shown herein outlines development of this new delivery systems for
the select pharmaceutical agents, diclofenac and celecoxib.
As a whole, formulation aspects of this study were directed at elucidating effects of polymer
type, drug and stabilizer concentration, and emulsifier effects on overall drug loaded NP characteristics.
Commonly reported NP characteristics including particle size, zeta potential, drug entrapment,
morphology, and in vitro release rates of various NSAID reformulations were determined. The
10

examination of particle size and zeta potential was performed using a NICOMP Zeta Sizer (Particle
Sizing Systems, Port Richey, FL, USA). In vitro drug release and drug entrapment investigations were
carried out using ultra violet spectrometry (Eppendorf Biophotometer, Hauppauge, NY, USA). Drug
loaded NP morphology was examined via transmission electron microscopy (Tecnai Philips
Transmission Electron Microscope; FEI, Hillsboro, Oregon, USA).
All experiments outlined above were used to study and elucidate the most effective and efficient
means of developing polymer drug encapsulated NPs of diclofenac or celecoxib. Major pit-falls and
difficulties were not expected during the formulation process. However, a trial and error process was
required to identify peak formulation parameters for polymer drug formulation. For example, variations
in stabilizer concentration can lead to altered particle characteristics. If a certain concentration of
stabilizer resulted in unsatisfactory particle characteristics (i.e. low zeta potential, reduced
encapsulation), formulations utilizing higher stabilizer concentrations were examined in an attempt to
achieve peak particle parameters. Other optimization techniques were also employed in an effort to
reach ideal particle characteristics.
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CHAPTER 2
Nanoparticles in Drug Delivery: Mechanism of Action, Formulation, and Clinical Application Towards
Reduction in Drug Associated Nephrotoxicity.
Dustin L. Cooper, Christopher M. Conder, and Sam Harirforoosh
Department of Pharmaceutical Sciences, Gatton College of Pharmacy, East Tennessee State University,
Johnson City, TN 37614

Abstract
Introduction: Over the past few decades, nanoparticles (NPs) have gained immeasurable interest in the
field of drug delivery. Various NP formulations have been disseminated in drug development in an
attempt to increase efficiency, safety, and tolerability of incorporated drugs. In this context, NP
formulations that increase solubility, control release, and/or affect the in vivo disposition of drugs, were
developed to improve the pharmacokinetic and pharmacodynamic properties of encapsulated drugs.
Areas Covered: In this article, important properties related to NP function such as particle charge, size,
and shape are disseminated. Also, the current understanding of how NP characteristics affect particle
uptake and targeted delivery is elucidated. Selected NP systems currently used in delivery of drugs in
biological systems and their production methods are discussed as well. Emphasis is placed on current
NP formulations that are shown to reduce drug induced adverse renal complications.
Expert Opinion: Formulation designs utilizing NP encapsulated drugs offer alternative
pharmacotherapy options with improved safety profile for current and emerging drugs. Nanoparticles
have been shown to increase the therapeutic index of several entrapped drugs mostly by decreasing drug
localization and side effects on organs. Recent studies on NP encapsulated chemotherapeutic and
antibiotic medications show enhanced therapeutic outcomes by altering drug degradation, increasing
systemic circulation, and/or enhancing cellular uptake. They may also reduce the distribution of
encapsulated drugs into kidneys and attenuate drug-associated adverse renal complications. The
usefulness of NP formulation in reducing the nephrotoxicity of nonsteroidal anti-inflammatory drugs is
an under explored territory that deserves more attention.

Keywords: nanoparticle, formulation, liposome, polymer, bioavailability, biodegradation,
nephrotoxicity, NSAIDs
Dustin L. Cooper, Christopher M. Conder, and Sam Harirforoosh 2014. Nanoparticles in Drug Delivery: Mechanism of Action, Formulation, and Clinical
Application towards Reduction in Drug Associated Nephrotoxicity. Expert Opinion on Drug Delivery doi:10.1517/17425247.2014.938046
Reprinted by permission of the publisher (Taylor and Francis Ltd, http://tandfonline.com) Ex. Opin. Drug Deliver, Volume 11, Issue 10, 2014.
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Article highlights.
‡Research into the functional aspects of particle science has led to increased interest in NP based
drug delivery for enhancement of the therapeutic effects of selected drugs.
‡Characteristic aspects of NPs enables the use of drug loaded NPs for improved targeting and
cellular uptake by altering particle properties such as drug lipophilicity, cell adhesion, receptor
binding, and endocytosis based drug uptake.
‡NP formulation can be achieved through differing methods of development based on drug,
particle type, characteristics, and delivery form. Several methods are employed in industry and
academia for successful development of liposomal and polymer based NP delivery systems.
Solvent evaporation techniques are commonly employed in both industry and academia for
successful development of a wide range of NP systems.
‡Altered degradation rates can lead to functional differences in drug effects and systemic
exposure. NPs have successfully altered pharmacokinetic and pharmacodynamics properties of
selected drugs, leading to the development of sustained drug delivery systems that work to
increase patient compliance and reduce the onset of drug induced side effects.
‡Nephrotoxic side effects are common for a number of prescribed medications. NP science has
shown enhanced beneficial aspects of known nephrotoxic drugs utilizing NP drug delivery. In
vivo, in vitro, and clinical trials have demonstrated improved renal effects in paclitaxel,
amphotericin B, and cyclosporine based drug regimens. These and other findings have led to
development of several FDA approved formulations showing improved clinical efficacy and
minimization of common drug side effects, suggesting further research into the effect of NP
formulation for improved clinical efficacy of other known nephrotoxic drugs such as NSAIDs.
This box summarizes key points contained in the article
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Introduction
Nanoparticles (NPs) are small particles that range in size from 10 nm to 1000 nm [1]. They contain
nanomolecular materials in which active ingredients are dissolved, entrapped, and/or encapsulated. At
present, NPs can be found in hundreds of different consumer products ranging from sunscreen and air
conditioners to processed food supplies [2]. Over the past few decades, NPs have gained recognition in
the medical field as an effective means of drug delivery and therapy [3].
Nanometer size range can effectively alter a substance’s physical, chemical, and biological
properties [4]. On the other hand, NP surface properties can be altered through the utilization of various
substances such as polysaccharides, proteins, and polymers [5]. The size and surface properties of NPs
can be optimized for given drugs. This opportunity allows the re-formulation of many different
therapeutics to new pharmaceutical products with a potential for increased activity and reduced toxicity
[6].

Active ingredients can be encapsulated within NPs of differing functionality and chemical structure.
This allows for the formulation of a multitude of NP based delivery systems [7] that can exhibit unique
properties related to their intended use. The ultimate objective of research in this area is to design a
suitable NP, i.e., NPs of appropriate size, chemical structure, and surface characteristics, that can
encapsulate clinically relevant amounts of an intended drug with enhanced drug kinetics and dynamics
in the biological system [4]. The choice of materials to be used for the production of NP formulations is
dependent on the desired functionality one wishes to achieve with respect to specific physicochemical
characteristics of a drug and its intended pharmacological activity [8]. In this manuscript, we discuss the
function and preparation of selected NP systems used in biomedical research. Emphasis is then placed
on the role of NP formulations in reducing renal side effects of commonly known nephrotoxic drugs.

Nanoparticle Mechanism of Action
NP drug encapsulation offers several advantages in creating effective means of drug delivery and
localization. NP traits such as particle size, surface charge, and shape play important roles in creating
effective NP delivery systems that function through a variety of mechanisms.

1.1. Effect of Particle Size
Particle size can affect the efficiency, biodistribution, and cellular uptake of various NP systems [9]. It is
thought that size parameters can play significant roles in the determination of cell interaction and
adhesion for various NPs. Size can also play an important part in degradation and elimination processes
of NPs. In certain NP systems, the primary aim is to avoid the reticuloendothelia system that targets
14

foreign bodies for degradation. Avoidance of this system results in an increase of total blood circulation
time and bioavailability. As such, it is important to note that nanoparticle size has been directly
correlated with clearance rate. As the size of NPs increase, the rate of clearance increases as well. It has
been shown that NPs with hydrophilic surfaces exhibiting a particle size less than 100 nm can
effectively avoid the mononuclear phagocytic system (MPS) [10]. MPS is a critical element in
physiological systems for the elimination of foreign substances. Blood serum contains opsonin proteins
which can efficiently bind to larger NPs and tag them for MPS degradation [11]. NPs that obtain small
particle diameter and hydrophilic properties can avoid opsinization and MPS degradation, thus
enhancing total blood circulation time [10, 11]. Nanometric particles can undergo extensive cellular uptake
in comparison to micrometric particles [12]. In a study conducted by Desai et al., it was shown that
nanoparticle uptake of an in situ rat intestinal loop model demonstrated 15 – 250 fold increases in
cellular uptake when compared to larger microparticles [13]. Other studies have shown positive particle
size influence in regards to cellular and tissue uptake. In these studies, it was demonstrated that only
nano sized particles underwent extensive uptake in comparisons to their larger, microparticle
counterparts [14]. Findings such as these demonstrate the influence and importance of particle size for
intracellular delivery of various active agents used within the realm of drug therapeutics.

1.2. Effect of Particle Charge
NP charge plays a critical role in the action and efficacy of NP delivery to and through cellular
membranes [15]. Stability of an NP system is facilitated through the degree of surface charge present on
NPs [16]. A highly charged system undergoes a much larger degree of repulsion between like charged
particles. This net repulsive force acts to stabilize and prevent NP aggregation. NPs formulated with
more pronounced surface charges have been shown to stabilize NP suspension and prevent particle
aggregation. Surface charge characteristics can determine NP degree of absorption as it has been found
that NPs with highly positive charges can interact with the anionic polyelectrolyte properties of mucus,
resulting in enhanced muco-adhesion and retention of NPs within the mucus layer. Investigational
studies performed with PLGA and poly vinyl alcohol formulated NPs have resulted in NPs with highly
negative surface charges, which may explain their high reabsorption ability through natural pathways.
Many cellular membranes are negatively charged. NPs formulated with known anionic polymers or
surfactants will be presented with higher net negative surface charge. This increased negative surface
charge will result in repulsion of the NP when it comes into the vicinity of cell membranes. As a result
of this repulsive force, cellular uptake becomes difficult and cellular adhesion is reduced. Positively
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charged nanoparticles experience opposite effects. The cationic NP facilitates membrane attraction and
adhesion, which creates favorable properties for cellular uptake via endocytosis or other mechanisms.

1.3. Effect of Particle Shape
In recent years, research has revealed that particle shape may have fundamental effects on the biological
properties of NPs [17]. In a study conducted by Geng et al., it was found that polymer micelles of shorter
stature showed an increased total blood circulation time following intravenous (IV) injection [18]. When
compared to longer micelles, shorter spheres also underwent a higher degree of cell uptake and
effectively delivered the drug, paclitaxel, to targeted tumor cells. Another study found that the length of
NP inversely influenced cellular adhesion. In that study it was found that as particle length increased the
subsequent binding of NPs decreased, suggesting that attachment and adhesion is a function of cellular
length [19]. These studies suggest the importance of NP shape in therapeutic outcomes in relations to
drug design and delivery. In NP development, characterization and design must not only pertain to
particle size or surface charge, rational design and analysis of shape effects on targeted NP outcomes
must be dually considered during NP drug delivery research.

1.4. Cell Targeting
Many biological targets for nanomedicines are large complex molecules such as membrane receptors
[20].

Biological processes are initiated through polyvalent interaction between these targeted receptors

and its appropriate ligand. Many NP formulations have been developed that largely overlook NP valence
capacitance and receptor interactions. However, some formulations such as dendrimer and polymer
based NPs have been documented to function through polyanionic receptor mediated targeting [15].
Dendrimer based NP systems have demonstrated targeted viral and cellular interactions via polyvalent
interactions with varying surface proteins [20]. Folate formulated polymer based NPs have been shown to
bind to overexpressed folate receptors common to tumor cells and initiate cellular entry [15]. Other
polymer formulated NPs have shown specificity for caveolae and clatherin proteins resulting in
endocytosis uptake via differing target mechanisms [21]. Polymeric micelles have demonstrated the
ability to target cancer cells and initiate cellular uptake while avoiding excess uptake in normal
epithelial cells [15]. This difference in cell type uptake is thought to be a result of NP differentiation of
endocytosis mechanisms common to each cell type [22]. Carcinogenic cellular uptake is initiated through
caveolae mediated endocytosis which is absent in normal cell lines. The caveolae targeting capacitance
of polymeric micelles enables drug uptake into cancerous cell lines while avoiding drug uptake in
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normal cells. As a result, cytotoxic drugs can be formulated in polymer based micelles for cancer
treatment that could avoid cytotoxicity of normal functional cell types

Characterization
New NP formula characterization is a vital and highly sensitive component in new drug development
and delivery. Some researchers can experience poor characterization studies as a result of undefined
methods or misinterpreted information [23]. The National Cancer Institute’s Nanotechnology
Characterization Laboratory (NCL) has taken steps in further streamlining nanoparticle formulation
safety and biocompatibility. The NCL functions as a strong resource for new formulation scientist in
hopes of avoiding common pitfalls in new NP design. In this review, characteristics and methods of
determination will be briefly discussed as it is important to understand the varying methods used in
academia and industry for identification of NP parameters. While this review offers a brief description
of characterization studies commonly done in NP formulation, it is far from exhaustive. Further inquiry
into proper characterization techniques should be directed towards NCL’s scientific bibliography and
published data on characterization [23].

1.5. Particle Size Characterization
Dynamic light scattering (DLS) is commonly used to determine NP size. DLS functions by measuring
Brownian motion and relates its velocity to NP size using the Stokes-Einstein equation [24]. Reported
results are expressed as mean particle size with a degree of particle homogeneity or polydispersity index
(PDI). A PDI value between 0.1 and 0.25 is indicative of small distribution ranges in particle size, while
PDI values greater than 0.5 suggest larger particle dispersity in relation to size [25]. Microscopy
techniques can also be used to accurately determine particle size, however the process is often times
more complicated, requiring several different sample preparation steps.

1.6. Determination of Zeta Potential
Measurements of particle charge, or zeta potential, are often accomplished by electrophorectic mobility
assays. NPs are surrounded by two separate liquid layers, the strong inner bound Stern layer and the
weak bound outer layer [25]. Electrophoresis applies an electrical current to an NP solution and measures
the degree of NP mobility, thus measuring the charge of the NP outer layer. Several different pieces of
equipment, such as Malvern zeta sizer and NICOMP particle sizing system, are used for particle charge
analysis [26]. In many instances, these systems serve a dual functionality by providing both particle
charge and particle size data analysis [27].
17

1.7. Measurement of Drug Release
The ability for an NP to release entrapped drug is critical in the overall functionality of NP derived drug
delivery. Measurements of NP release kinetics enable scientists to properly analyze new NP system
behavior and evaluate their potential efficacy in clinical use. NP release can occur through three distinct
pathways: desorption of surface bound drug, polymer matrix erosion, and drug diffusion [25]. Primary
routes of drug release often occur through matrix diffusion and/or erosion, while desorption of surface
bound drug is commonly attributed to the rapid burst release seen in many NP formulations.
Analysis of NP release is commonly done using sample separation or membrane dialysis techniques
[28].

In sample separation, NP solutions are emerged within a fixed volume of medium and placed on an

electronic shaker or stir plate. Solution samples are taken at various time points and centrifuged or
filtered while fresh media is added to the NP solutions. Following sample centrifugation and/or
filtration, the resultant supernatant is analyzed for free drug content [27]. Dialysis methods measure NP
release as a function of continuous diffusion across a membrane [25]. The method involves the use of
select membrane pore size and molecular weight cut off parameters for proper NP and free drug analysis
[28].

The dialysis membrane procedure consists of two compartments, a donor compartment and receptor

compartment. NP solutions are placed within the donor compartment and fresh medium is placed within
the receptor compartment. At various time points, samples are collected from the receptor compartment
and analyzed for free drug content. Solution analysis is carried out through several different methods
including high performance liquid chromatography and ultra violet spectrometry [25, 27, 28].

1.8. Morphology
NP morphological and shape characteristics are important for studying NP presence, surface
characteristics, topography, degree of aggregation, and direct analysis of particle shape [29]. NP
morphology studies are commonly carried out utilizing transmission electron microscopy (TEM) or
scanning electron microscopy (SEM) techniques [27, 30]. In these techniques, small amounts of NP
samples are placed on select TEM or SEM carbon film, with or without reflective coating [29]. Thin
samples are required to allow transparency of the electron beam, as such, samples are usually coated
lightly on microscopic film or if nanoparticle solutions are employed, allowed to dry before
visualization [29]. TEM allows researchers to quickly and accurately achieve size distribution and particle
density information for new NP formulations.
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Nanoparticle Transport
A NP placed externally to cells can interact with cellular plasma membranes and enter inside the cell via
passive diffusion or endocytosis [15] (Fig. 2.1). Endocytosis involves a multi stage process in which
extracellular components interact with cellular membranes forming invaginations. These invaginations
then become pinched to form endosomes or phagosomes (depending on route of transportation) and
delivered to targeted compartments within the cell.

1.9. Passive Diffusion
The process of passive diffusion can occur when a nanoparticle dissolves across the lipid membrane of a
cell (Fig. 2.1). Diffusion can depend upon several factors related to nanoparticle characteristics. NP
surface charge can influence the degree to which substances passively diffuse across the lipophilic
plasma membrane of various cells [31]. Previous studies have demonstrated the ability of charged
nanoparticles to facilitate a three to four fold increase in uptake across a cholesterol containing lipid
bilayer. Further studies have elucidated diffusion of NPs within cells based on their influences on tight
junctions. Sonaje et al. demonstrated the influence of NP formulation on the opening of tight junctions.
It was shown that NP treatment resulted in slightly increased apical membrane space which facilitates
paracellular transport of insulin [32]. These results indicate that the use of NPs to deliver drugs across
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cellular membranes via diffusion mechanisms may offer advantages over current drug delivery
strategies.

1.10.

Endocytosis

The process of endocytosis is divided into two broad categories; pinocytosis (receptor mediated and/or
macropinocytosis) and phagocytosis [33] (Fig. 2.1). Receptor mediated endocytosis involves the
engulfment of receptors in conjunction with their associated ligand, into a coated pit. Clatherin protein
coated pits are the more commonly associated receptor mediated endocytic pathway and are often
referred to as the “classical” form of receptor mediated endocytosis. The clatherin coated pits are
primarily responsible for uptake of essential nutrients such as cholesterol and iron [12]. Caveolae consist
of structural caveolin proteins that function as integral membrane proteins and can be found in
abundance in adipocytes, muscle and epithelial cells [15]. Caveolae mediated endocytosis functions by
engulfing molecules that bind to caveola surfaces. Unlike clatherin dependent endocytosis, caveolae
proteins do not disassociate from the vesicle following endocytosis [9]. Macropinocytosis processes
allow for the engulfment of larger solute macromolecules and can measure as wide as 5 µm.
Phagocytosis generally refers to cellular uptake of large microparticles such as microorganisms and dead
cells, which are ingested and transported via phagosomes. It is important to note that phagocytosis is
generally restricted to specialized mammalian cells, such as macrophages, that play an important role in
the detection and elimination of foreign substances.

Types of Nanoparticles
Nanodelivery systems are generally divided to two classes of lipid and polymer based delivery systems.

1.11.

Lipid Based Nano-Delivery Systems

Lipid based NPs have been extensively used for increased oral, topical and intravenous drug delivery [2].
Most commonly used lipid based nano-delivery systems are liposomes and small lipid based
nanoparticles (Fig. 2.2A and 2.2B, respectively).
Liposomes are spherical vesicles composed of phospholipid bilayers with a particle size distribution
between 10 – 1000 nm [34] (Fig. 2.2A). Liposomes are formed when phospholipids are dispersed in an
aqueous solution. When phospholipids are placed in water the hydrophilic head group interacts with the
polar medium resulting in the formation of multi and unilayered vesicles [35]. These vesicles are
composed of biological lipid bilayers that form a spherical shell [35]. Because of their entrapment
capabilities, liposomes are a highly useful tool for pharmaceutical delivery. Liposomes are normally
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developed by drying down lipids from an organic solvent, then dispersing the lipids through aqueous
medium in the presence of a detergent, followed by purification [36]. The most extensively used method
for dispersion in liposome formation is probe or bath sonication. Characteristics of the liposome lipid
bilayer can allow fusion of the liposome to cell membranes, thus instigating direct delivery of material
(i.e. drug) inside the cell [37].

Medical studies looking at liposomal effects of anti-cancer drugs demonstrated an increase total drug
circulation and tumor exposure time brought about by increased tissue retention [38]. In fungal infections,
it has been shown that amphotericin B liposomes function to enhance cellular adhesion and aid in
penetrating fungal cell walls and enhance entrance into cellular cytoplasm, suggesting cell and tissue
specific targeting [39]. As such, liposomes have been extensively used as carriers for many different
molecules within the pharmaceutical industry. Because of their high degree of biocompatibility, low
toxicity, site specificity, and ability to entrap both hydrophobic and hydrophilic compounds, liposomes
have gained immense interest in commercial drug delivery [36, 40].
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Solid lipid systems have become a major focus in drug delivery research. Their high degree of
biocompatibility, physiochemical properties, and ability to enhance absorption of hydrophobic drugs
through lymphatic uptake has made them popular compounds to utilize in drug carrier systems [40].
Compared to liquid oil solutions, solid lipids allow less formulation based drug mobility and as such, a
much greater control in drug delivery [41]. Aside from effects on drug release, it should be noted that
solid lipids and solid lipid nanoparticle (SLN) matrices are composed of physiological lipids which can
effectively reduce acute and chronic toxicity associated with other forms of drug delivery [42] (Fig.
2.2B). SLNs are produced by mechanically dispersing lipids in water or an aqueous surfactant solution,
which allows for select advantages over common liposomes and other various forms of NPs [42, 43] (Fig.
2.2B). Other advantages claimed with SLNs include: increased drug stability, high drug payload, and
ease of sterilization and large scale production [42]. The enhanced stability of SLNs decreased the
propensity of drug leakage and offers a delivery option that is more biodegradable and compatible and
less toxic when compared to other nano-based delivery options [7, 43]. SLNs have an average particle size
below 500 nm [42].
Lipid based drug conjugates are one of the most widely accepted methods for development and
delivery of hydrophilic drugs. Other lipid delivery systems such as SLN experience low levels of
hydrophilic drug incorporation and have low drug loading capacitance based on polarity [44]. Lipid drug
conjugates (LDCs) are able to convert water soluble drugs into insoluble lipid drug conjugates by
conjugation of an amino or hydroxyl group of the drug of choice to the carboxyl group present in a lipid
core. LDCs are generally formed in bulk via covalent linkage or salt formation then converted into NPs
via high pressure homogenization [44]. Studies have shown that the use of LDCs in drug formulation can
effectively increase gut permeability and enhance oral delivery of select therapeutic agents via reduced
first pass exposure and increased lymphatic absorption. Other studies have demonstrated the use of
LDCs in effective increases in drug uptake across the blood brain barrier. A study conducted by Olbrich
et al. showed that lipid conjugated diminazene demonstrated less cytotoxic effects and increased blood
brain barrier passage when conjugated to a lipid matrix through enhanced LDL receptor activation [45].

1.12.

Polymer Based Nanodelivery Systems

Polymer based NPs are superior to liposomes primarily because of tissue and organ specific targeting [46]
(Fig. 2.3A). The ability to absorb and coat polymeric formed NPs with differing substances such as
target specific ligands for tissue specificity and polyethylene glycol for increased hydrophilic properties,
allows investigators and drug development specialists a wide variety in reducing toxicity and inducing
specific functions for a particular drug or compound.
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Many biodegradable polymers are available for polymer based NP formulation. Poly (lactic acid) (PLA),
poly (glycolic acid) (PGA), and poly (lactic-co-glycolic acid) (PLGA) polymers are a few of the more
successfully used biodegradable polymers [46]. PLGA, PLA, and PGA are commercially available for use
in various drug delivery systems. The use of PLA, PGA, and PLGA in NP formulations allows
for particle manipulation without increasing toxicity as they are all biodegradable polymers that undergo
hydrolysis to lactic acid and/or glycolic acid [47]. The formation of Krebs cycle intermediates associated
with these polymers creates minimal physiological toxicity as they are easily and efficiently
metabolized. Differing NP characteristics such as particle size, shape, and zeta potential can be produced
according to parameters set forth by the specific synthesis process [48]. Degradation time for polymers
can vary depending upon their molecular weight [47, 49]. Of all the biodegradable polymers currently
available, PLGA seems to be the more common choice for polymer based NP synthesis and has
appeared in several commercial formulations (Table 2.1) [50].
PLA is commonly used to a lesser extent due to its prolonged degradation rate, while PGA is used when
fast degradation and hydrolysis processes are warranted. Particle size distributions of polymeric NPs
usually range from 50 – 500 nm [51]. Unlike liposomes, polymeric NP characteristics usually employee a
smaller size diameter allowing for enhanced systemic circulation and reduced recognition and
degradation by the mononuclear phagocytic system [34]. Polymer based NPs have also shown an
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enhanced stability and resistance to drug leakage at normal physiological conditions when compared to
liposomes [52]. Inclusion of polymer formulated liposomal NP systems have been proposed and
researched as a means of enhancing liposome resistance to drug leakage and prevention of potential
cytotoxic effects [53]. Studies have shown that polymerization of liposomal systems can enhance
liposomal resistance to drug leakage at temperatures of 40 °C.

Polymers have also been used in dendrimer delivery systems. Dendrimers (Fig. 2.3B) are highly
branched molecules with multiple arms extending from a central core [54]. Aside from their highly
branched structure, dendrimers also possess unique characteristics such as controlled mutlivalency,
defined molecular weight and globular structure. The multivalency characteristics of dendrimers allows
attachment of several different drug molecules and targeting groups to the periphery of the dendrimer.
As such, dendrimers offer several advantages in drug delivery. Recently, polymeric and dendrimer
science has combined to develop a new class of molecule called dendronized polymers [55]. Through
polymeric conjugation, scientists can effectively alter the hydrodynamic size of dendrimers, all while
maintaining particle size homogeneity and increasing drug loading capacitance [56]. Dendronized
polymers have displayed favorable results in intracellular protein and drug delivery [57]. In vitro and in
vivo studies have shown increased chemotherapeutic efficacy in doxorubicin (DOX) loaded dendronized
polymers. Compared to I.V. delivery of free DOX, DOX loaded dendronized polymers have
demonstrated a 10 fold reduction in cellular toxicity, while showing a 9 fold increase in tumor uptake
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[56].

The increased anti-tumor activity of DOX loaded dendronized polymers is thought to be resultant

from favorable alterations in the pharmacokinetic profile of DOX via alterations in total blood
circulation time. Dendrimer based NP formulations have also been used successfully to target various
viral based receptors that functions to inhibit cellular binding and entrance. Vivagel is a dendrimer based
drug delivery system developed exclusively by Starpharma that contains uniquely designed polyvalent
properties [20]. This dendrimeric system functions primarily through polyanionic surfaces to target
various receptors. It has been shown to attach to viral surfaces and prevent binding to cell surfaces,
thereby preventing cellular uptake and infection. As a result, this unique NP formulation has shown
potent inhibitory effects in HIV and HSV studies while demonstrating relatively safe and tolerable
effects [58, 59]. Given these results, dendronized polymers could also show favorable results in modulating
the effects of various other drugs, making them ideal candidates for use in drug delivery. Polymeric
micelles are formed through the self-assembly of amphiphilic macromolecules and act as efficient
carriers for highly hydrophobic drugs [40] (Fig. 2.3C). The hydrophobic core of the micelle can be loaded
with small hydrophobic drugs through simple emulsion or solvent evaporation techniques [60]. Their high
capacity to solubilize largely lipophilic drugs make them extremely versatile tools for increasing the
aqueous solubility of drugs as well as increasing and altering drug bioavailability. When factoring in the
inherent and modifiable properties of polymeric micelles, they become extremely valuable commodities
in the realm of drug therapeutics and delivery [61]. Polymeric micelles can be modified to control the rate
of drug release, thus increasing blood circulation time and avoiding host defenses that would target
drugs for degradation [62]. Relative to existing solubilizing agents such as Cremophor EL, polymeric
micelles may demonstrate increased safety parameters for I.V. administration, allowing for alterations in
drug dosing parameters of highly toxic and water insoluble drugs. It has been found that polymeric
micelles also function by inhibiting p-glycoprotein in the gastrointestinal tract and brain, providing a
way to facilitate increased drug absorption from the gut and absorption into the brain. These
characteristics make polymeric micelles well suited and highly regarded for drug delivery purposes.
Like lipid based NP systems, drug conjugation utilizing polymer formulated NPs for enhanced
delivery have been investigated [63] (Fig. 2.3D). Drug conjugated polymer NPs have been used in the
field of research in dual purpose circumstances. A study conducted by Feng et al. demonstrated the use
of the positively charged fluorescent polymer PFO and poly glutamic acid for the development of
conjugated DOX NPs [64]. In the study, poly glutamic acid conjugates functioned to effectively delivery
DOX to the site of action via endocytosis uptake, while the PFO conjugate enable successful
visualization of drug/NP conjugate localization. DOX conjugated polymer NPs have also been shown to
facilitate tumor cell localization and controlled drug release via enzymatic and pH sensitive methods. A
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recent study showed polymer conjugates of DOX bound via pH sensitive hydrazone or enzymatically
degradable amide bonds facilitated differing anti-tumor mechanistic actions [65]. The mechanism of
differing actions was thought to be a result of amide linkage formulations tendency to directly penetrate
the plasma membrane leading to accumulation of DOX throughout subcellular compartments [65, 66].
Conjugate NPs formulated with pH sensitive hydrazone bonds demonstrated cellular uptake via
endocytosis and pinocytosis mechanism, leading to DOX release in low pH endosomes and lysosomes
[65].

As such, it is believed that the differing mechanisms of action for both conjugate formulations could

potentially lead to synergistic anti-tumor effects with low drug specific toxicity [67].

1.13.

Metal Based Systems

Metal based NPs have been commonly seen in industry and academia. Of particular interest has been the
utilization of gold based NPs for cancer treatment. The characteristic shine that is common with gold
NPs and the ease of localization and visibility makes them a great tool for future research, both
diagnostically and preventatively, in cancer therapy and treatment [68]. The dynamic in binding affinity
of gold NPs to non-cancerous cells versus cancer cells makes them excellent choices for cancer
identification as gold based NPs have a 600 percent greater affinity for cancer cells than for
noncancerous cells. The abundance of cancer cells that exhibit epidermal growth factor receptor (EGFR)
makes it possible to conjugate or bind an antibody for EGFR to gold NPs, thus allowing them to attach
to their targeted cancer cells [69]. Various gold based nanoparticles are being used in preclinical and in
vitro studies for the delivery of other chemotherapeutic compounds as well [70]. Drugs such as 5fluorouricil and docletaxel have been reformulated into gold nanoparticle delivery systems for the
treatment of colon and squamous cancer lines. A recent study demonstrated the use of gold NPs
conjugated with partially polymerized liposomes for DOX delivery. The study showed an enhanced
killing effect of MDA-MB-231 breast cancer cell lines upon controlled release of DOX loaded
polymeric-gold NPs [53]. Gold NPs have also been used for the induction of hypothermic injury in
various cancer cell lines and have been shown to be effective in the treatment of superficial tumors. As
such, clinical trials using hypothermic techniques coupled with gold NPs are currently under way for
patients suffering from oropharyngeal malignancies.
Platinum NPs are easily synthesized through the reduction of hexachloroplatinate with hydrogen gas
[71].

One of the most surprising characteristics of platinum NPs involves their antioxidant properties [72].

Platinum NPs have been found to exude antioxidant properties and prolong the life span of C. elegans
during experimental analysis. Recently, platinum based NPs have demonstrated increased efficacy of
chemotherapeutic agents in the treatment of a variety of breast and ovarian cancer cell lines [73].
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Platinum nanoparticles were shown to reduce toxicity profiles commonly associated with
chemotherapeutic drug use and significantly increase drug anti-tumor efficacy. These findings suggest
that the beneficial properties of platinum NPs may extend beyond their antioxidant properties and offer
novel advantages in drug delivery.
The magnetic properties and biocompatibility of superparamagnetic iron oxide nanoparticles
(SPION) has facilitated their emergence into the field of biomedicine as a promising agent in medical
therapeutics and diagnostic. The high magnetization properties of SPIONs allows for their use as
excellent image probes for MRI contrast and imaging. It has been found that SPION based contrast
agents induced longer delineation of tumor margins and enhanced tumor localization in comparison to
conventional contrast agents such as gandolinium [74]. As such, FDA approval has been given to several
iron oxide based imagining agents such as Lumiren and Endorem for use in the medical field [74, 75]. Iron
oxide has also found successful use in the field of disease treatment [74]. Drug loaded iron oxide NPs
have shown enhanced caspase-8 activity in human cancer cell lines with increased permeation of cellular
membranes brought about by tight junction disruption [76]. Other studies have shown further cellular
permeability induced by iron oxide based nanoparticles as well as enhanced tumor cell targeting via
surface bound peptide interactions, making iron oxide based NP formulation an important potential aid
in disease treatment [74].

1.14.

Carbon Nanotubes

Carbon nanotubes (CNTs) consist of a hexagonal arrangement of carbon atoms consisting of one or
more walls of graphene sheets [77]. The highly toxic nature of first generation CNTs made them
unsuitable for application in a variety of fields such as drug delivery. However, recent advances in CNTs
formulation has enable researchers to significantly reduce the toxicity profiles commonly associate with
CNT delivery [78]. Through surface modification and changes in covalent and non-covelent
intermolecular interactions, researchers may be able to synthesize altered CNTs with reduced toxicities
profiles. Given the capabilities of reducing toxic side effects, research into drug delivery using CNT has
risen in popularity over the past few years. CNT has shown improvements for the delivery of a variety
of different molecules [77]. Mehra et al. used multi-walled CNTs in the reformulation of DOX for cancer
treatment. In the study it was found that drug formulations utilizing CNTs presented with increased total
circulation time, sustained release and enhanced DOX cytotoxicity when compared to standard DOX
dosages [78]. Sustained release of other molecules has also been reported [79]. CNTs are thought to
facilitate cellular uptake by translocating across cellular membranes through either endocytosis or nonendocytosis pathways [77]. CNTs have demonstrated the ability to enhance permeability and extravasate
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in tumor tissue. When coupled with their large surface area and subsequent high loading capacity, these
properties make them ideal candidates for new approaches to drug delivery.

1.15.

Quantum Dots

Quantum dots (QDs) are described as basic semiconductors that exude electrical characteristics with a
particle size distribution between 2 – 10 nm [80, 81]. These specific dots are developed and manufactured
through various techniques such as fabrication, viral assembly of inorganic nanocrystal, and
electrochemical assembly involving ionic reactions between electrolyte and metal structures [80]. QDs
contain a larger number of sites in which active material can be attached. As a result of the large number
of active sites contained on QDs, multifunctional properties can be developed through tethering and
modification of an assortment of bioactive agents [82]. Recent studies have shown that pegylated QDs
enhanced cellular uptake and increased NP trafficking through targeting of the caveolae mediated
endocytic pathway [15]. Other studies have demonstrated the use of QDs in tissue specific targeting of
tumor cells by tethering prostate specific antigen to QDs [82]. Based on the increasing versatility of
quantum dots, their use in comparison to less versatile organic dyes are rising exponentially [80].

1.16.

Protein Based Systems

Protein based NP systems have been developed to aid the delivery of certain drugs to specific, localized
compartments [83]. Abraxane is an albumin bound NP containing the chemotherapeutic agent paclitaxel
which was approved by the FDA for use in relapsed and metastatic breast cancer [15]. Abraxane
functions by taking advantage of receptor mediated endocytosis of tumor cells [84]. It selectively binds to
GP-60 albumin receptors located within cell caveolae. This binding facilitates movement into the
interstitial space where it is engulfed by secretory tumor proteins. In turn, these tumor proteins are taken
up by tumor cells resulting in cell specific tumor cytotoxicity [85].

Nanoparticle Preparation
Various means of preparation, solvent evaporation, high pressure homogenization, nanoprecipitation,
salting out, microemulsion, and detergent removal have been identified for NPs. As the field grows at a
substantial rate, a wide variety of preparation methods have been developed for nano-material
formulation. However, there are several key properties of NPs and drug encapsulation that one must
keep in mind. The selection of material to be used for formulation depends on several factors involving,
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but not limited to, the nanometric size of particles needed, surface characteristics required, properties of
the drug one wishes to encapsulated and the bioavailability and toxicity limits required [46]. In this
article, we discuss only solvent evaporation and high pressure homogenization.

1.17.

Solvent Evaporation

Solvent evaporation techniques are the most commonly used techniques for polymer based NP
preparation [51]. Solvent evaporation is most prevalently used in biotech and pharmaceutical industries
and represents the most common technique seen in the literature. There are two types of procedures
typically used when preparing NPs through solvent evaporation, single emulsion and double emulsion
[46].

Single emulsion preparation involves oil in water emulsions, while double emulsion techniques

utilize water in oil in water emulsions [46]. Once solvents are properly prepared, they are homogenized
and evaporated to facilitate the formation of solid NPs. Solid NPs are collected by ultracentrifugation
then washed with distilled water to remove additional surfactants. After additional surfactants are
removed the mixture is lyophilized.
The step by step solvent evaporation process is as follows: Polymers are dissolved in organic
solvents, followed by addition of the drug of choice [46]. The organic mixture is added into a water based
phase containing an emulsifier or stabilizer (oil/water). The mixture is then homogenized or sonicated
for complete homogenization, after which the solution is then stirred constantly for several minutes to
evaporate organic phase and harden newly formed NPs. Finally, solutions undergo centrifugation or
filtration to harness newly formed drug particles (Fig. 2.4).
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1.18.

High Pressure Homogenization

High pressure homogenization (HPR) is a technique commonly used in the preparations of SLNs and
liposomes [41]. HPR can be performed as either a hot homogenization or a cold homogenization (Fig.
2.3). For hot HPR techniques, a drug is usually dissolved in lipid being melted at 5-10°C above its
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melting point. The melt is then dispersed under a hot aqueous surfactant solution that is being heated at
the same temperature. The resulting solution is then homogenized to form a hot oil in water
nanoemulsion and cooled to room temperature to enable recrystallization and the formation of lipid
vesicles (Fig. 2.5A). In cold HPR, the drug containing melt is cooled to form a solid lipid. The solid
lipid is then ground to form microlipid particles. Microlipids are then dispersed in a cold aqueous
surfactant solution and homogenized at or below room temperature to facilitate SNL formation (Fig.
2.5B).
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Nanoparticles for Enhancing Drug Pharmacokinetics and Pharmacodynamics
1.19.
Biodegradation
A key aspect in NP abilities to control and alter pharmacokinetic and pharmacodynamic parameters is
biodegradation. NP biodegradation is thought to occur primarily through hydrolytic mechanism that can
be enhanced or reduced dependent upon various factors. For polymer based NPs, molecule weight
(MW), ratio, and composition play a key role in determining the extent or rate or degradation. A study
conducted by Kamei et al. utilized two differing weights of PLGA (10,000 and 20,000 MW) in
determinations of altered degradation rates [86]. It was found that the low molecular weight polymer
exhibited a rate of degradation of 8 days, while the degradation of high MW polymer was doubled to
that of 16 days. It is thought that molecular weight ranges can play a role in polymer degradation as well
[87].

Compounds with a large MW range present with higher levels of carboxylic end groups that could

function to increase catalytic degradation. As such, polymers of a wider MW range would be expected
to facilitate or increase degradation whereas polymers with smaller more compact MW ranges would
present with less carboxylic end groups thus reducing catalytic activity and degradation.
Composition also plays an important role in overall release kinetics. A study conducted by Tabata et
al. examined the biodegradation of particles composed of lactic acid polymer, glycolic acid polymer, or
copolymers consisting of differing ratios of lactic and glycolic acid [88]. It was found that the rate of
particle degradation was controlled by altering monomer composition [87]. Particles containing 50%
glycolic acid and 50% lactic acid elicited the fasted rate of degradation, while particles composed of
higher or lower concentrations of glycolic acid were found to degrade at a slower rate. As such, drugs
entrapped within a polymer matrix can elicit sustained release profiles through slow diffusion from the
polymer core and degradation of the polymer matrix [12, 87]. The rate of degradation of NPs can vary
dependent upon several factors allowing for the design of various NP rates of drug release based on
polymeric MW ranges or core polymer composition [89].

1.20.

Bioavailability Improvement

Oral solid drug delivery systems are a common and convenient form of drug administration. For an
increasing numbers of drug molecules, the oral route is complicated by solubility, bioavailability, and,
stability concerns that necessitate higher oral doses or parenteral administration [90]. These
considerations are particularly applicable to Biopharmaceutics Classification System (BCS) Class II
drugs that exhibit poor solubility and high permeability [91]. For a lot of drugs, the use of NPs is meant to
improve oral bioavailability by decreasing particle size and increasing relative surface area to facilitate
drug dissolution. A recent study looked at oral absorption and the effects of high pressure homogenized
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nanosuspensions of itraconazole. It was found that drug nanoization resulted in a faster rate of
dissolution accompanied by an increase in total blood plasma concentrations [92]. A recent study looked
at the inclusion of orally dosed GLP-1 agonist in nanomatrices composed of Eudragit and silica [93]. The
highly sensitive nature of GLP-1 to acidic conditions of the stomach makes it a relatively poor candidate
for oral administration. However, when GLP-1 was adsorbed on the surface of solid silicon based
nanoparticles and encapsulated with the pH-sensitive polymer, Eudragit, it displayed a five-fold higher
degree of mucosal adhesion and proteolytic stability within the gastrointestinal tract.

1.21.

Pharmacokinetics Alterations

Characterization of drug NP in vivo kinetics is further complicated by the unique attributes of each drug,
excipient, and route of administration. A simplification of available reports is the use of NPs increases
the area under the curve (AUC), a common measure of total drug exposure. Improvements in
bioavailability relative to current preparations helps explain these observations [94]. It is important to
note that as bioavailability increases, access to various body compartments increase as well [95]. Changes
in distribution will profoundly impact other pharmacokinetic parameters, including drug clearance (Cl),
volume of distribution (Vd), maximum drug plasma concentration (Cmax), time of maximum drug
plasma concentration (Tmax), elimination rate constants, and drug half-life. Drug concentration-time
profiles for NPs can reflect either immediate or extended release characteristics as a function of baseline
solubility when compared to commercially available preparations. Drugs with poor solubility, like BCS
Class II compounds, will have their solubility enhanced by nanoparticles and achieve a higher Cmax in
less time (lower Tmax) [91]. The converse is true of more hydrophilic compounds, where NPs will delay
a compound's dissolution [96]. Other extended release applications use pH-dependent matrices to help
conserve stability throughout the gastrointestinal tract [4].

1.22.

Side Effect Reduction

Traditional examples of improved side effect profiles include amphotericin and cyclosporine [97]. More
recent studies have addressed the severe toxicity associated with chemotherapeutic agents. Cremophor
EL is a toxic solubilizing agent used in the formulation of highly lipophilic drugs, such as paclitaxel [98].
Recent studies comparing new nanometric formulations of paclitaxel with Cremophor based vehicle
formulations have shown favorable results in drug response, safety and side effect profiles. Paclitaxel
nanosuspension has also been shown to exhibit distinct distribution profiles that may complement their
tolerability in the foundation of new applications in liver, lung, or spleen metastases [95]. NP renal side
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effects in regards to chemotherapeutic and antibiotic reformulation are further expounded on within this
review.

7.4.1. Antibiotic Drug Induced Nephrotoxicity
Amphotericin B is a popular anti-fungal agent that is considered the gold standard for the treatment of
an assortment of fungal based diseases [99]. However, amphotericin B use has been linked to a variety of
adverse side effects, the most common being nephrotoxicity [100]. Nephrotoxic effects of amphotericin B
are very high and can produce acute renal failure symptoms in patients [101]. Previous studies have
shown that 49 - 64 % of patients administered amphotericin B developed acute renal failure symptoms
[102].

When compared to baseline, 29 % of patients show serum creatinine concentrations greater than

250 mmol/L [103].
Due to the extreme toxic nature of amphotericin B, reformulation tactics have been used to minimize
toxic side effects. Studies have demonstrated that the use of biodegradable NPs significantly reduce
nephrotoxic side effects of amphotericin B while still maintaining potent anti-fungal activity [104].
Several studies have looked at specific renal cell effects of amphotericin B formulated NPs. In one
study, lactate dehydrogenase release was measured as an indicator of cell damage. It was shown that
amphotericin B formulated NPs reduced cellular lactate dehydrogenase release, indicating reduce
nephrotoxicity [105]. Another study showed reduced protein expression in cell lines treated with base
amphotericin B in comparison to NP formulated amphotericin B, indicating mechanistic actions on
protein synthesis as a possible means of NP reduced nephrotoxicity [105, 106].
Vancomycin is a potent antibiotic drug used in the treatment of multi-drug resistant bacterial
infection [107]. Although its high efficacy in regards to treatment of infection is ideal, it has been shown
to increase serum creatinine concentrations and cause severe nephrotoxic side effects [108]. Poly ethylene
glycol is an excipient commonly used to stabilize and solubilize pharmaceutical products, when low
molecular weight variants are wanted. Recent studies have shown that solubilized formulations of
vancomycin utilizing D-mannitol and poly ethylene glycol effectively reduced renal side effects of
vancomycin when administered at the nephrotoxic dose of 400 mg/kg in rats [109]. Groups receiving
reformulated vancomycin showed no marked changes in BUN parameters and experienced no
alterations in histological parameters of the kidneys when compared to control. At twice the daily
clinical dose, renal tissue accumulation of vancomycin increased substantially in groups receiving
conventional formula (653.8 ± 186.0 µg/g) when compared to groups receiving vancomycin
reformulation (442.9 ± 120.6 µg/g) [110]. These findings suggest that vancomycin reformulation reduces
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renal damage and prevents nephrotoxic side effects through modifications of drug release and tissue
targeting.

7.4.2. Chemotherapeutic and Immunosuppressive Drug Induced Nephrotoxicity
Cyclosporine (CsA) is a potent chemotherapeutic and immunosuppressing agent used for the prevention
of graft and organ transplant rejection and the treatment of certain cancers and autoimmune disorders
[111].

CsA is a highly toxic drug that may induce sever nephrotoxic symptoms ranging from acute kidney

failure to chronic renal disease [112]. As such, it is important to develop a delivery system that could
serve to alter drug efflux, tissue accumulation, and system circulation for avoidance of adverse effects
[104, 113].

Several studies have reported the benefits of polymeric micelle cyclosporine encapsulation on

pharmacokinetic parameters as well as drug induced nephrotoxicity symptoms [114, 115]. In a study
conducted in 2005, it was found that volume of distribution and clearance values of micelle encapsulated
cyclosporine was 10 and 7.6 fold lower than conventional formulas, while tissue accumulation of
cyclosporine in the kidneys experienced a 1.4 fold reduction in comparison to groups receiving standard
drug delivery [114].
Tacrolimus is a potent immunosuppressive drug. [116]. Originally marketed for the prevention of
organ transplant rejection, tacrolimus has recently gained wide spread attention for its use in the
treatment of inflamed bowel disease (IBD) [117]. Recent studies discovered that the immunosuppressive
effect of tacrolimus was not selective to inflamed tissue [117]. As a consequence of tacrolimus nonselectivity, it was found to cause severe nephrotoxic symptoms in patient receiving drug treatment for
IBD. Interestingly, the effectiveness of NP formulations on reducing nephrotoxic side effects commonly
associated with tacrolimus use has been reported. NP reformulation of tacrolimus has been successfully
used for the development of tissue specific drug delivery and enhancement in phagocytosis mediated
cellular uptake [118]. It has been shown that PLGA formulated tacrolimus NPs can effectively target
lymphatic T cells for enhanced immunosuppressive properties [119]. A recent study looked at both PLGA
and Eudragit formulated tacrolimus nephrotoxicity and found that drugs treated with NP formulated
tacrolimus exhibited similar creatinine and BUN levels as compared to untreated controls [117].
Cisplatin is a highly effective chemotherapeutic agent used in the treatment of various cancers [120].
The most common side effect associated with cisplatin use is nephrotoxicity of the proximal tubule [121].
As such, altered formulations of cisplatin for patients receiving chemotherapy treatments are highly
desirable to prolong quality of life and drug effectiveness [122]. Several studies have been performed on
the use of NPs and cisplatin encapsulation with promising results. Cisplatin incorporated polymeric
35

micelles have been shown to reduce or eliminate nephrotoxic side effects while prolonging its antitumor activity [123]. Rats receiving cisplatin polymeric micelle formulations showed no marked changes
in nephrotoxic parameters such as BUN, creatinine, or tubular damage and necrosis when compared to
rats receiving control [124]. Cisplatin is thought to effect renal toxicity through up regulation of reactive
oxygen species (ROS) and increases in oxidative stress [125]. Recent studies have shown the ability of
NPs to increase effectiveness of ROS scavengers during co-administration with cisplatin. ROS
scavengers such as selenium have been shown to prevent or reverse cisplatin induced nephrotoxicity
above control when co-administered as NP encapsulated product [126]. Cisplatin is highly reabsorbed in
the kidneys [121, 127]. The degree of drug reabsorption is thought to play a role in the onset of nephrotoxic
side effects associated with cisplatin use [127]. It is thought that liposomal formulated cisplatin functions
to reduce or diminish tubular reabsorption of cisplatin resulting in a reduction in nephrotoxic side
effects. A recent clinical human study looked at the benefit of dual combination of paclitaxel and
liposomal formulated cisplatin in comparison to traditional formulated cisplatin with paclitaxel [127]. The
study showed a marked reduction in toxic side effects, including nephrotoxic effects, with adverse side
effects mainly occurring in patient groups receiving traditional formulation. A statistically significant
decrease in nephrotoxic side effects was noted in groups receiving liposomal reformulated cisplatin
when compared to traditional cisplatin formulation (P < 0.001).
Another chemotherapeutic agent, DOX, is one of the most important drugs used for the treatment of
malignancies and tumors [128]. It has been shown that NP formulated DOX effectively enhances systemic
circulation time, increases cellular drug uptake via macropinocytosis, and possibly down regulates P-gp
efflux [129]. Formulation alterations involving the use of lipomers and NPs have demonstrated favorable
outcomes in regards to increased bioavailability, decreased toxicity, and increase in kidney tissue
specific antioxidant capacitance of doxorubicin [130-132]. Similar to co-administration of cisplatin and
selenium, these studies show elevated antioxidant parameters along with reduced levels of lipid
peroxidation in renal tissue samples of rats receiving orally formulated NP-Dox compared to
conventional formula [130]. These findings suggest that NPs may play a role in both direct and indirect
means of renal adverse effect prevention.

7.4.3. Potential Use of Nanoparticle Formulations in Decreasing Renal Side Effects of
Nonsteroidal Anti-Inflammatory Drugs
Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), has been successfully formulated for
ocular, transdermal and colonic delivery using NPs with promising results [133-135]. Oral formulations of
diclofenac have been developed using polymer based NPs that altered pharmacokinetic parameters
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resulting in lower systemic exposure and faster absorption in comparison to standard diclofenac
formulations [4]. A recent phase 2 study using diclofenac loaded NPs showed increased tolerability and
enhanced drug efficacy and pain relief in patients suffering from acute dental pain [136]. Diclofenac
loaded SLNs have also demonstrated enhanced systemic circulation and increased permeation in ocular
delivery [137]. Indomethacin, another non-selective NSAID, has shown results in NP formulations as
well. In recent experiments, NP encapsulated indomethacin has demonstrated increased bioavailability,
prolonged drug release, and a higher degree of anti-inflammatory activity [138]. Recent NP conjugates
utilizing indomethacin have shown enhanced cellular uptake compared to base indomethacin. In a study
conducted by Li et al. indomethacin was successfully conjugated to heparin, which resulted in increased
indomethacin uptake into human nasopharyngeal carcinoma cell lines via increased drug permeability
and endocytosis pathway uptake [139].
Celecoxib is a highly metabolized cyclooxygenase (COX)-2-selective inhibitor known to increase
risk of cardiovascular and renal side effects [140, 141]. As a result of its high rate of metabolism, higher
dosages of celecoxib are often required to reach effective concentrations at the site of action [142].
Several studies involving celecoxib entrapped NPs have been performed that elucidate their
effectiveness at overcoming celecoxib bioavailability issues [91, 143]. A study conducted by Morgen et al.
showed that orally administered NP loaded celecoxib resulted in an increase in bioavailability and faster
time to peak plasma concentrations [91]. Another study showed that intra-articular injections of celecoxib
formulated small lipid NPs enhanced site of action and drug retention in patients suffering from joint
pain [144]. Additionally, two other studies demonstrated increased anti-inflammatory properties and
tumor growth inhibition of celecoxib entrapped NP formulations during subcutaneous delivery [145].
Celecoxib loaded NPs have shown the ability to undergo strong binding and cellular uptake via nonendocytosis pathways in HT-29 cancer cells [146]. Cytoplasmic and nuclei localization was also observed
in HT-29 cell lines as a consequence of non-specific interactions between the charged surfaces of NPs
and the negatively charged cellular membrane.
NP formulated NSAIDs offer a wide variety of benefits in terms of altered pharmacokinetic
parameters. Their impact on NSAID related gastrointestinal side effects are well documented. It has
been shown that NP formulated NSAIDs decrease incidences of gastric irritation and ulceration in
comparison to conventional delivery systems [147]. Conversely, the use of NP formulations in NSAID
therapy for carcinoma treatment has shown favorable results. Recent studies show the use of celecoxib
loaded NPs resulted in 78% to 95% reduction in cell proliferation with a marked increase in apoptosis in
colon cancer cell lines [146]. Interestingly, even though renal side effects are some of the more adverse
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occurrences associated with NSAIDs, the beneficial effects of NP formulated NSAIDs on renal and
cardiorenal side effects are yet to be elucidated.

Conclusion
Nanoparticle formulation presents many advantages for drug delivery. Depending upon individual needs
and interest, scientist can easily modify NP formulations for a variety of different compounds. The ease
of use in developing NPs makes them ideal for utilization within multiple areas of research. NPs offer a
plethora of biological advantages. They can protect drugs from damage and oxidation, act as a drug
stabilizer, increase tissue specific targeting, and aid in diffusion. Variations in surface modifications for
NPs allow flexibility in drug design and optional modifications based on individual research needs. NP’s
can improve the pharmacokinetic and pharmacodynamics profiles of a variety of drugs and can reduce
drug toxicity and increase drug safety parameters. NP formulations offer a highly feasible alternative in
the realm of new drug development. They have been shown to effectively work in reducing major side
effects in many applicable drugs of today. As such, the use of NPs in new drug formulation offers a
promising alternative to side effect, risk reduction and overall patient safety and quality of life.

Expert Opinion
NP use in drug delivery is increasing exponentially as the elucidation of their effectiveness progresses in
the field of medicine and bioscience. The use of NPs offers the medical researcher a plethora of
alternative avenues in the investigation and elucidation of effects in drug delivery on clinical efficacy
and outcomes. As such, researchers are investigating the use of NPs in a range of medical avenues from
image enhancement to skin graft procedures [148]. The potential for NP based drug delivery is virtually
limitless and is measurable only by our current understanding of mechanistic and molecular properties
that facilitate NP function. In the future, NP drug delivery should find inclusion into a number of
prescription based medical products above and beyond those currently seen in the literature and the
medical community today. At present, the pharmaceutical industry is investigating altered drug delivery
methods for new and currently patented drugs as a means to offset exponential cost in novel new drug
development and prevention of attrition [149]. Changes in formulation design and drug delivery have been
found to effectively increase the efficacy and therapeutic use of various drugs. The current
understanding of NP based drug delivery designs lends itself to industrial utilization to spur economic
growth and/or offset economic loss brought forth by new drug development. These altered delivery
methods can provide companies with avenues to change overall effectiveness and functionality of
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current popular medicines used in multiple disease based therapies. As such, the use of NP technology
should experience significant growth in industrial sectors not only for their ability to increase current
drug effectiveness but also for their ability to facilitate new targeted delivery and stimulated economic
growth.

Although seldom addressed in such reviews, it is important to note that production cost and
model scale-up for reformulated NP designs would present itself as a major hurdle in the continuation of
any NP drug creation. While the examples illustrated within the context of this article are promising in
regards to the use of NPs as novel treatment alternatives for the future, several formulations have not
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processed beyond pre-clinical studies based on large scale production cost and NP formulation
reproducibility. Fortunately, the advent of new and emerging FDA regulated NP based drugs has led to
an increase in industrial capabilities in NP production (Table 2.2).
Currently marketed NP drug designs have paved the way for easier transition of model scale up
for a variety of new NP drug products that may come in the future. Unfortunately, not all NP systems
have been recognized in a mass market approach, leaving avenues of scale up and mass production
susceptible to select NP systems.
Further research into differing avenues of NP delivery must be highlighted for a complete
understanding of most effective routes of administration. At present, studies done with NP reformulated
drugs have focused primarily on oral, intravenous, or transdermal delivery. Research into the effective
avenues of NP formulated drug administration must be taken into account in order to properly
understand the pinnacle effects a new drug delivery system utilizing NPs can offer. NPs can alter
various properties of a drug, which in turn affects the traditional method of drug delivery. It is important
to highlight differing modes of administration to properly gauge effects of NP drug reformulation on
delivery. For example, the use of PLGA is known to impart hydrophobic properties of NP encapsulated
drugs based on the extent of lactic acid content [150]. The alteration in drug lipophilic properties can
theoretically act to alter a drugs best means of delivery. As such, dependent upon the investigators
chosen NP system for delivery, emphasis should be placed on not only the effects of NP encapsulated
drug delivery but the effect of NP encapsulated drugs in various delivery methods. Further clarification
in best fits for modes of delivery will further strengthen use of NPs in newly developed pharmaceutical
products.
In this article, we have highlighted many examples of drug induced nephrotoxicity, summarized
in Table 2.3. The beneficial aspects of NP formulated alternatives in renal complications seen within this
review supports the possibility of creating viable drug alternatives in hopes of quenching and/or
reducing major treatment side effects. Unfortunately, further studies are still needed to clarify the extent
of their benefits and the overall best practice in terms of NP design. Exact mechanistic approaches for
the reduction of renal side effects noticed with NP entrapped drugs are not completely understood at the
present time. Further investigation into the mechanistic effect NP design has on drug excretion, kidney
accumulation, and cellular uptake is warranted to fully understand pharmacodynamics and
pharmacokinetic effects in relation to nephrotoxicity and onset of renal side effects. Also, renal
complications in relations to NSAID consumption are commonplace for a variety of COX inhibitors.
Surprisingly, few, if any studies have been performed looking at known COX inhibiting NP
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formulations and their effects on renal function. Further studies to elucidate the effectiveness of NP
formulations on NSAID induced nephrotoxicity are highly warranted.
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Figure Legends
Figure 2.1. Simplified schematic representation of cellular uptake showing passive diffusion or
pinocytosis and phagocytosis invagination pathways.
Figure 2.2. Structural diagram of liposomal bilayer (A) and small lipid nanoparticle (B).
Figure 2.3. Schematic diagram demonstrating multiple polymer based NP systems including (A)
polymer based NP with lipophilic core, (B) dendrimer based NP with multivalent branching arms, (C)
polymeric micelles containing a hydrophilic outer shell with corresponding hydrophobic inner core, (D)
and drug-polymer conjugate systems.
Figure 2.4. Schematic representation of solvent evaporation processes commonly used in NP production
showing separate organic and aqueous phase solution with dissolved constituents, and formation of
particle dispersion.
Figure 2.5. Diagram showing the process of (A) hot homogenization and (B) cold homogenization
techniques.
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Abstract
Drug based nanoparticle (NP) formulations have gained considerable attention over the past decade for
their use in various drug formulations. NPs have been shown to increase bioavailability, decrease side
effects of highly toxic drugs, and prolong drug release. Nonsteroidal anti-inflammatory drugs such as
diclofenac block cyclooxygenase expression and reduce prostaglandin synthesis, which can lead to
several side effects such as gastrointestinal bleeding and renal insufficiency. The aim of this study was
to formulate and characterize diclofenac entrapped poly(lactide-co-glycolide) (PLGA) based
nanoparticles. Nanoparticles were formulated using an emulsion-diffusion-evaporation technique with
varying concentrations of poly vinyl alcohol (PVA) (0.1, 0.25, 0.5, or 1%) or
didodecyldimethylammonium bromide (DMAB) (0.1, 0.25, 0.5, 0.75, or 1%) stabilizers centrifuged at
8,800 rpm or 12,000 rpm. The resultant nanoparticles were evaluated based on particle size, zeta
potential, and entrapment efficacy. DMAB formulated NPs showed the lowest particle size (108 ± 2.1
nm) and highest zeta potential (-27.71 ± 0.6 mV) at 0.1 and 0.25% respectively, after centrifugation at
12,000 rpm. Results of the PVA based NP formulation showed the smallest particle size (92.4 ± 7.6 nm)
and highest zeta potential (-11.14 ± 0.5 mV) at 0.25% and 1% w/v, respectively, after centrifugation at
12,000 rpm. Drug entrapment reached 77.3 ± 3.5% and 80.2 ± 1.2% efficiency with DMAB and PVA
formulations, respectively. The results of our study indicate the use of DMAB for increased nanoparticle
stability during formulation. Our study supports the effective utilization of PLGA based nanoparticle
formulation for diclofenac.
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Introduction
Over the past decade, there has been an increased interest in particle manipulation and nanosizing of
selected drugs. In particular, polymeric nanoparticle formulation has gained an increasing amount of
public attention in the fields of drug delivery and pharmaceutics. In recent years, the application of
polymer based nanoparticles in drug formulation has garnered immense attention. Industry has focused,
in large part, on the utilization of biodegradable polymer based nanoparticles as effective drug delivery
agents because of their ability to prolong drug release, increase drug bioavailability, decrease drug
degradation and reduce drug toxicity [1]. Research in nanoparticle drug formulations has focused
heavily on the use of poly(lactic acid) (PLA), poly(D,L glycolide) (PLG), and poly(lactide-co-glycolide)
(PLGA) (Fig. 3.1) based nanoparticles because of their tissue compatibility, low toxicity, and high rate
of hydrolysis [2]

.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed drugs in
the world [3]. NSAIDs are pharmaceutical agents that exert analgesic and anti-inflammatory effects
through the inhibition of the cyclooxygenase family of enzymes. Diclofenac is a NSAID that is
commercially available in its sodium (Fig. 3.2) or potassium salt form [4].

Like other NSAIDs, common side effects associated with the use of diclofenac include
gastrointestinal lesion formation, and renal damage [4]. Interestingly, studies have shown a reduction in
gastrointestinal and renal side effects associated with various drugs when encapsulated into polymer
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based nanoparticles and administered orally [5-7]. These results demonstrate the effectiveness of
nanoparticle formulation in reducing and/or eliminating potential adverse side effects associate with
orally delivered toxic drugs.
Diclofenac nanoparticle reformulation has been used for ophthalmic and transdermal delivery with
promising results [8-11]. The purpose of this study was to develop and characterize a new oral
formulation of diclofenac using polymer based nanoparticles. Nanoparticles were synthesized using a
solvent-evaporation technique and the effects of centrifugation speed and concentrations of two different
stabilizers, poly (vinyl alcohol) (PVA) (Fig. 3.3) or didodecyldimethylammonium bromide (DMAB)
(Fig. 3.4), was examined for effects on entrapment efficiency, particle size, and stability.

Materials and methods
2.1. Materials
PLGA (50:50 copolymer compositions; MW 30,000 Da), didodecyldimethylammonium bromide
(DMAB), poly vinyl alcohol (MW 89,000 Da) and 15 mL Corning centrifuge tubes were purchased
from Aldrich (St. Louis, MO, USA). Diclofenac was obtained from MP Biomedical (Solon, OH, USA).
Ethyl acetate and HPLC grade water were purchased from Fischer Scientific Laboratory (Fair Lawn, NJ,
USA). Phosphate buffer pH 7.0 was purchased from EMD Chemicals Inc. (Gibbstown, NJ, USA). 0.2
micron syringe filters were obtained from Millipore Corporation (Carrigtwohill, Ireland).
2.2. Method of Nanoparticle Preparation
Nanoparticles were prepared by an emulsion – diffusion – evaporation technique [5] with slight
modifications. Briefly, 45 mg of diclofenac and 50 mg of PLGA were placed in 3 mL ethyl acetate and
stirred at 750 rpm for 30 minutes. Varying concentrations of PVA (0.1, 0.25, 0.5, or 1% w/v) or DMAB
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(0.1, 0.25, 0.5, 0.75, or 1% w/v) stabilizers were placed within 6 mL of HPLC grade water heated to 140
°C and stirred at 750 rpm until fully dissolved. The organic phase was then added to aqueous phase in a
drop wise manner under moderate stirring then sonicated for 5 minutes at 20 kHz using a sonic
dismembrator (Fischer Scientific, Fair Lawn, NJ, USA). To facilitate diffusion, 25 mL of water was
added to each emulsion under constant stirring at 750 rpm. Emulsions were stirred at 750 rpm for 4
hours to insure complete organic phase evaporation. After which, each emulsion was centrifuge (8,800
rpm or 12,000 rpm) and supernatant was collected.
2.3. Particle Size and Zeta Potential
Particle size was measured by dynamic light scattering using a Nicomp particle sizer (Particle Sizing
Systems, Port Richy, FL, USA). Zeta potential was estimated on the basis of electrophoretic mobility
under an electrical field. All measurements were performed in triplicates.
2.4. Entrapment Efficiency
To measure the amount of diclofenac nanoparticle entrapment, the amount of diclofenac present within
solutions following end stage centrifugation was calculated. Diclofenac stock solution dissolved in
methanol (200 mg/mL) was used to construct a standard calibration curve (10,000 – 2,000,000 ng/mL).
Pure methanol was used as a blank experiment before UV measurement, after which total NP drug
content was calculated using the standard curve after control for blank NPs. Quantification was
performed by UV-spectrophotometry (Eppendorf Biophotometer, Hauppauge, NY, USA) with
absorbance set at 280 nm. Entrapment efficiency was calculated using the following equation:
Entrapment Efficiency = (Amount of diclofenac entrapped within nanoparticles/Total amount of
diclofenac used for synthesis) X 100

2.5. Effects of Centrifugation Speed and Stabilizer Concentration on Nanoparticle Properties
NPs were formulated with five different concentrations of DMAB (0.1, 0.25, 0.5, 0.75, or 1 % w/v) and
four different concentrations of PVA (0.1, 0.25, 0.5, or 1% w/v). Effect of stabilizer concentrations and
two centrifugation rates (8,800 or 12,000 rpm) on zeta potential, particle size, and entrapment efficiency
was evaluated.

2.6. Nanoparticle Morphology Characterization
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Shape and surface morphology of NPs were examined with a transmission electron microscope (TEM)
(Tecnai Philips Transmission Electron Microscope; FEI, Hillsboro, Oregon, USA). NP solutions were
vortex mixed and 2 µL of suspension was placed on a 100 mesh copper grid covered with Formvar film
(Electron Microscopy Sciences, Hatfield, Pennsylvania). Samples were kept under ventilation for 2
hours to allow for complete drying, than examined by TEM at 80 kV.

2.7. In Vitro Drug Release Study
In vitro release of diclofenac sodium was carried out as previously described with slight modification
[12,13]. Briefly, 2 mL of solution containing diclofenac formulated nanoparticles were placed into 15
mL centrifuge tubes containing 8 mL phosphate buffer. Suspensions were then placed on an electronic
shaker set at 100 rpm. At various time points, 2 mL of release medium was removed and replaced with
the same volume of fresh medium. Isolated samples were centrifuged at 4,400 rpm for 5 minutes and
filtered through a 0.2 micron syringe filter. Analysis was carried out using a UV spectrophotometer set
at 280 nm with empty nanoparticle solutions used as control.
2.8. Data treatment

Data is represented as mean ± standard deviation (SD). The unpaired Student’s t-test was used to
analyze cumulative release data for identical stabilizer concentrations.

Results
3.1. Synthesis and assembly of diclofenac loaded PLGA based nanoparticles
The synthesis of PLGA based nanoparticles was achieved through an emulsion – diffusion – evaporation
technique. A solution of diclofenac and PLGA dissolved in ethyl acetate was added to an aqueous
solution containing stabilizer in a drop wise manner, followed by sonication and moderate stirring for 4
hours to ensure complete organic phase evaporation. The synthesis of PLGA polymer based
nanoparticles using ethyl acetate as the primary solvent has been reported before [5,14,15]. In the
present study, PLGA NPs containing diclofenac were prepared using DMAB and PVA as stabilizers.
To determine optimal nanoparticle production, varying levels of DMAB and PVA stabilizer
concentration along with varying centrifugation speeds were evaluated in the determination of peak
nanoparticle synthesis (Table 3.1). Aqueous to organic phase ratios of 1:1 were found to elicit particle
aggregation during formulation process (data not shown). As a result, a direct 1:2 ratio of organic to
aqueous phase solution was used for nanoparticle synthesis.
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3.2. Influence of centrifugation and DMAB stabilizer on nanoparticle size and stability
Particle size and zeta potential measurements were conducted using a NICOMP Zeta Sizer System with
DMAB formulated polymer NPs (Fig. 3.5).

Measurements revealed low particle size and increased zeta potential stability with low stabilizer
concentrations. Zeta potential reached peak measurements at 0.1 and 0.25% DMAB concentration. A
maximum zeta potential was reached at -27.7 ± 0.6 mV using 0.25% DMAB formulation (Table 3.2).
Particle size was lowest using 0.1% DMAB concentrations and highest at 0.5 and 0.75% DMAB
concentrations (Table 3.2). Interestingly, centrifugation speed was found to positively affect stability
and particle size. As centrifugation speed was increased from 8,800 rpm to 12,000 rpm, there was a
further increase in zeta potential and decrease in particle size when compared to lower centrifugation
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speed. Stability and particle size still followed the same trends as seen in lower centrifugation speeds in
relation to stabilizer concentration with the exception of 0.25 and 0.5%, which showed an increase in
zeta potential and reduction in particle size (Table 3.2).

3.3. Influence of centrifugation and PVA stabilizer on nanoparticle size and stability
Measurements of NP formulated nanoparticles using PVA stabilizer revealed lower stability and lower
particle size parameters in comparison to DMAB formulations (Table 3.3). At 8,800 rpm centrifugation
speed, particle size and zeta potential showed inverse trends in relations to stabilizer concentration. As
stabilizer was increased zeta potential decreased, conversely particle size increased with increasing
stabilizer concentrations. Higher centrifugation speeds maintained similar patterns with the exception of
0.25 and 1% PVA concentrations (Table 3.3). Formulations at 0.25% showed a slight reduction in
particle size, reaching its lowest diameter at 92.4 ± 7.6 nm. Also, 1% stabilizer formulations showed a
higher degree of stability with increasing zeta potential, reaching a peak zeta potential of -11.1 ± 0.5 mV
(Table 3.3).
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3.4. Effects of stabilizer concentrations on diclofenac entrapment
Amount of drug entrapment was determined by UV-spectroscopy in varying stabilizer concentrations.
DMAB formulated NPs reached peak entrapment at low w/v concentration. Entrapment levels with
DMAB reached as high as 77.3 ± 3.5% and were seen at 0.1% w/v DMAB concentrations. When the
concentration of DMAB increased, a linear reduction in overall drug entrapment and entrapment
amounts was seen (Fig. 3.6A) (Table 3.4).
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Conversely, as centrifugation speed was increased, slightly lower levels of drug entrapment were
obtained for each formulation. Linear regression in overall drug entrapment percentages were still
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maintained (Fig. 3.6B) (Table 3.4).

Measurements of drug entrapment utilizing PVA stabilizers showed similar findings to DMAB
formulations. Drug entrapment levels reached 73.6 ± 0.9% and 75.2 ± 1.7% entrapment for PVA
formulations at 0.25 and 0.5% w/v (Table 3.5). When centrifugation speed was increased, drug
entrapment of diclofenac reached 80.2 ± 1.2% entrapment at a lower 0.1% PVA formulation (Table 3.5).
Increases in centrifugation speed increased drug entrapment at 0.1%, 0.25% and 1% PVA
concentrations. Drug entrapment efficiency reduced from 75.2 ± 1.7% to 28.6 ± 1.9% in 0.5% PVA
formulations when speed in centrifugation was increased (Table 3.5).

3.5. Nanoparticle Shape and Surface Morphology
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Morphology studies were carried out using 0.25% DMAB and 1% PVA concentrations. These stabilizer
concentrations were chosen based on zeta potential and nanoparticle stability characteristics. The TEM
images of blank and diclofenac loaded DMAB (Fig. 3.7A and 3.7B, respectively) and PVA (Fig. 3.8A
and 3.8B, respectively) formulated NPs support the particle size data obtained by our characterization
studies performed with the zetasizer. DMAB formulated NPs have a distinct, spherical shape composed
of a dense core with diclofenac loaded NPs showing a slightly increased size diameter due to drug
incorporation (Fig. 3.7B). Drug incorporation did not affect overall particle shape. Morphology of PVA
formulated NPs show a high degree of shape variation and aggregation in both blank NPs (Fig. 3.8A)
and diclofenac loaded NPs (Fig. 3.8B).
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3.6. Stabilizer Influence on In Vitro Diclofenac Release
In vitro release studies were performed on two different stabilizer concentrations for both DMAB and
PVA formulated NPs. Stabilizer concentrations of 0.1% and 0.25% centrifuged at 12,000 rpm were
chosen based on their efficient level of drug entrapment and best fit mean representation of particle
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stability of each stabilizer group. The in vitro release of both DMAB and PVA formulated diclofenac
loaded NPs are given in Figs. 3.9 and 3.10.

The statistical comparison of the percentage drug release values obtained with the different nanoparticle
stabilizer compositions at specific sampling times revealed significant difference (P < 0.05) in both
stabilizer concentration groups. DMAB formulations at 0.1% showed an initial significant increase in
drug release in comparisons to 0.1% PVA formulations during the initial 4 hr time frame (Fig. 3.9) (P <
0.05). After 24 hrs, total drug release was similar with a cumulative release of over 80% achieved for
both groups (Fig. 3.9). The drug release of NPs formulated with 0.25% PVA showed a similar pattern of
initial release of diclofenac in comparison to DMAB formulation (Fig.3.10). Both formulations
experienced greater than 40% release during the first hour of the study. However, after the first initial
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hour, cumulative release began to increase significantly in PVA formulated groups at each successive
time point (P < 0.05). PVA formulations reached an average cumulative release percentage of 88%,
while DMAB formulation reached an average cumulative release of 73% (Fig. 3.10).

Discussion
The adverse cardiovascular, gastrointestinal, and renal side effect caused by NSAID consumption has
restricted the clinical use of these important drugs. The main objective of our research was to
reformulate and develop a new nanoparticle formulation for diclofenac sodium that could replace
traditional capsule and tablet oral administration and minimize or delay the onset of adverse side effects
commonly associated with NSAIDs. Nanoparticles have been used for the development of a variety of
different drug delivery systems [1,14,16-20]. Recent studies have shown the use of polymer based
nanoparticles in the reformulation of diclofenac for ophthalmic and colonic us with promising results
[13,21-23]. Topically formulated diclofenac delivery systems have also been used with success for the
treatment of a variety of inflammatory skin diseases [24-26]. Diclofenac delivery utilizing small lipid
nanoparticles showed promising results in the realm of drug reformulation and enhanced drug delivery
systems [27,28]. Interestingly, the use of microspheres in reformulation has demonstrated enhanced drug
entrapment and drug release of diclofenac [29]. One study showed that the use of Eudragit and alginate
polymer systems improved drug release profiles and enhanced the physical properties of tablet
compaction [30], while other studies have demonstrated a high degree of stability and morphology in
microsphere development with the use of PVA [31,32]. However, to date, reformulation characteristics
of diclofenac nanoparticles for oral delivery has yet to be extensively examined.
In this study, diclofenac loaded PLGA NPs were formulated following an emulsion – diffusion –
evaporation technique using DMAB or PVA as stabilizers. Stabilizers function as emulsifying agents
that can offset the surface tension between organic and aqueous phases, thereby increasing drug
solubility and nanoparticle encapsulation. Because of this understanding, a variation in the level of
stabilizer used can equate to variations in nanoparticle characteristics during the formulation process
[5,33-36]. In our study, we formulated drug loaded NPs at varying levels of PVA and DMAB stabilizer
concentrations to elucidate the most efficient formulation characteristics for maximum drug
encapsulation, stability and size.
A study conducted by Cetin et al. [12] demonstrated low levels of diclofenac NP stability and
entrapment efficiency when using a Eudragit®L100 and Eudragit®L100 PLGA based nanoparticle
formulation with PVA as stabilizer. Consequently, they also showed that variations in polymer
concentrations did not effectively alter NP characteristics to a measurable degree. Based on these
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findings diclofenac formulated NPs appeared to offer complications in achieving premium NP
characteristics during formulation [12]. In our study, drug loaded NPs were prepared at varied DMAB
(0.1, 0.25, 0.5, 0.75, or 1% w/v) and PVA (0.1, 0.25, 0.5, or 1% w/v) concentrations. Nanoparticle size
was at its largest when DMAB concentrations were between 0.25, 0.5, and 0.75% w/v. Consequently,
zeta potential and stability of NPs were highest when DMAB concentrations were lower (Table 2).
Surprisingly, our study demonstrated diclofenac loaded NP particle sizes of 108 and 92.4 nm with
DMAB and PVA, respectively. Zeta potential stability measurements reached as high as -27.7 ± 0.6 mV
in formulations using DMAB, and were substantially lower in formulation utilizing PVA stabilizers
(Tables 3.2 and 3.3). These results are further supported by previously published findings in which a
Eudragit®RS100 based formulation of diclofenac was used for nanoparticle characterization. It was
found that variations in Eudragit concentrations effectively altered drug entrapment and particle
diameter characteristics for diclofenac loaded NPs. Alterations in diclofenac to Eudragit concentrations
resulted in variable measurements in particle diameter, ranging in size from 103 ± 6 to 170 ± 36 nm,
which are consistent with the size variations of 92.4 ± 7.6 to 216 ± 3.4 nm found within our study [37].
Our morphological analysis showed distinct, well defined diclofenac loaded NPs when formulated with
0.25% DMAB stabilizer (Fig. 3.7B). The visualization of 1% PVA formulations showed distinct NP
aggregation (Fig. 3.8A and 3.8B). These findings are consistent with particle properties of low zeta
potential noticed during our characterization studies performed with the zetasizer. A more pronounced
zeta potential value has a tendency to stabilize and prevent particle aggregation [38]. It is known that
particles with a larger charge experience a much higher degree of repulsion from other like charged
particles [38]. The high degree of particle aggregation of 1% PVA formulations are indicative of poor
stability and reduced zeta potential [38,39], which is in line with our initial findings. TEM scaling
measured particle sizes within the range reported by zetasizer analysis for both formulations (Table 3.2
and 3.3). These findings suggest the use of specific DMAB concentrations in effectively formulating
stable PLGA based diclofenac loaded NPs.
Entrapment efficiency is a crucial step in the characterization of an effectively formulated drug
encapsulated nanoparticle. In our study, the result of drug encapsulation efficiencies with differing
stabilizer concentrations and centrifugation speeds is shown in Tables 3.4 and 3.5. Our study showed
high degrees of drug encapsulation for both DMAB and PVA formulations. In DMAB formulations,
drug encapsulation followed a linear decline in the amount of drug entrapped in relation to the amount
(Figs. 3.6A and 3.6B) or concentration (Table 3.4) of stabilizer used. The highest level of entrapment
reached was 77.3 ± 3.5% and was seen with DMAB concentrations of 0.1% w/v. It is important to note
that stabilizing agents are important factors in determining the entrapment efficiency of lipophilic drugs.
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Stabilizers function by forming molecular micelles through interactions between hydrophobic portions
of the stabilizers with the hydrophobic core of the NP. In other studies, it was shown that as
concentrations of DMAB increases, entrapment of lipophilic drug increases in response [5]. Our
findings have demonstrated the opposite in regards to entrapment, suggesting that the high polarizability
of diclofenac effectively works against the micelle formation properties of DMAB resulting in a
reduction in drug entrapment as DMAB concentrations increase.
Measurements of entrapment efficiency in formulations utilizing PVA as stabilizer showed
similar results to those obtained with DMAB. An entrapment efficiency of 80.2 ± 1.2% was seen at PVA
concentrations of 0.1% following centrifugation at 12,000 rpm (Table 3.5). Interestingly, while
entrapment efficiency remained high, zeta potential measurements remained close to zero, indicating
low levels of stability (Table 3.3). Two possible explanations of our findings exist. One possibility is the
presence of residual PVA. The presence of residual PVA on the nanoparticle surface has been found to
mask charged groups existing on the surface of PVA formulated nanoparticle [40]. Thus, residual PVA
may effectively create a shield between the nanoparticle and its surrounding medium, resulting in lower
zeta potential measurements that still maintain higher levels of entrapment [40,41]. A second possibility
is the correlation between zeta potential and nanoparticle stability. Zeta potential measurements closer to
zero represents a high degree of non-stability with a weak surface charge surrounding the NP. It is
highly possible that NPs degrade and break during the centrifugation process, in turn causing entrapped
drug to leak from the NP into the medium. The leakage of free drug into the medium could result in
higher levels of spectrophotometric drug detection during entrapment studies.
Results of our in vitro study showed an increased initial diclofenac burst release for NPs
formulated with 0.1% DMAB when compared to 0.1% PVA (Fig.3. 9). Inverse results were seen with
stabilizer concentrations at 0.25%. Formulations with PVA at 0.25% concentration demonstrated a
marked increase in drug release following one hour of agitation when compared to 0.25% DMAB
formulation. Drug release from nanoparticles can occur through several means such as desorption of
drug close to the surface of the nanoparticle, diffusion through the polymer matrix, or matrix erosion [2].
The fast release of diclofenac in 0.1% DMAB concentrations may be due to diclofenac polarity and
increased levels of diclofenac absorbed closer to the surface of our DMAB nanoparticles [42]. The
stunted release noticed in 0.25% DMAB formulation could be attributed to increased electrostatic
adhesion of the drug molecules to the polymeric matrix. It has been shown that particles with larger zeta
potential demonstrate higher adhesion of drug molecules to the polymeric matrix as a result of
electrostatic adhesion [2]. It is possible that adhesion may be taking place within these particles that may
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reduce diffusion of diclofenac within the PLGA nanoparticle core after exposure to dissolution medium
[42,43].
The purpose of our study was to elucidate a novel formulation for diclofenac sodium using
polymer based nanoparticles. Our results are based on NP formulations using two different stabilizers at
varying concentrations at two distinct centrifugation speeds. As such, our results are limited to NP
characteristics utilizing PVA and DMAB stabilizers. It is entirely possible that the use of other
stabilizing agents could result in alterations of NP characteristics above what has been seen in our study.
Solvents play a critical role in the determination of NP characteristics as well. In our study, we
utilized ethyl acetate as our primary organic solvent for NP preparation. Our choice of solvent was based
on evidence seen in previous publications which utilized ethyl acetate in conjunction with other solvents
on the determination of NP characteristics. Ethyl acetate was shown to be most effective at creating
stable NPs in conjunction with the use of PLGA and DMAB as stabilizer [5,44]. The use of differing
solvents would alter pH characteristic of formulation medium. Since our focus was on the salt form of
diclofenac it is possible that alteration in organic solvents could alter ionization and solubility of
diclofenac sodium, leading to differences in particle size, stability and entrapment.

Conclusions
In summary, our findings revealed the fact that diclofenac loaded PLGA NPs could be prepared utilizing
low concentrations of PVA and DMAB stabilizers. Formulation was achieved through a very basic and
simple evaporation – diffusion technique utilizing ethyl acetate as organic solvent. In comparisons to
previous reports, the NPs of diclofenac developed in this study provided adequate diclofenac entrapment
levels and showed superior levels of stability with a marked reduction in overall particle size. Diclofenac
loaded PLGA NPs could be used as an alternative to existing oral delivery methods and aid in offsetting
deleterious side effects common to NSAID use.
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Figure Legends
Figure 3.1. Chemical structure of poly (lactide-co-glycolide) [45]
Figure 3.2. Chemical structure of diclofenac sodium [46]
Figure 3.3. Chemical structure of poly vinyl alcohol (PVA) [47]
Figure 3.4. Chemical structure of didodecyldimethylammonium bromide (DMAB) [48]
Figure 3.5. Particle Sizing Systems NICOMP analysis of diclofenac loaded, PLGA based, 0.1% DMAB
NP formulation.
Figure 3.6. Entrapment effects of varying DMAB stabilizer concentrations. Entrapment efficiency after
8,800 rpm centrifugation of diclofenac loaded NPs (A); Entrapment efficiency after 12,000 rpm
centrifugation of diclofenac loaded NPs (B). Values are expressed as mean ± standard deviation.
Figure 3.7. Morphological Analysis of 0.25% DMAB Formulated NPs. Transmission electron
microscopy image of empty NPs formulated with 0.25% DMAB stabilizer (A); Transmission electron
microscopy image of diclofenac loaded NPs formulated with 0.25% DMAB stabilizer (B).
Figure 3.8. Morphological Analysis of 1% PVA Formulated NPs. Transmission electron microscopy
image of empty NPs formulated with 1% PVA stabilizer (A); Transmission electron microscopy image
of diclofenac loaded NPs formulated with 1% PVA stabilizer (B).
Figure 3.9. NP Formulation In-vitro Drug Release Study with 0.1% Stabilizer Concentrations. In vitro
release profile of diclofenac sodium in phosphate buffer of pH 7 from 0.1% PVA formulated NPs and
0.1% DMAB formulated NPs (mean ± SD, n = 3, p < 0.05).
Figure 3.10. NP Formulation In-vitro Drug Release Study with 0.25% Stabilizer Concentrations. In vitro
release profile of diclofenac sodium in phosphate buffer of pH 7 from 0.25% PVA formulated NPs and
0.25% DMAB formulated NPs (mean ± SD, n = 3, p < 0.05).
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Abstract
Polymer based nanoparticle formulations have been shown to increase drug bioavailability and/or reduce
drug adverse effects. Nonsteroidal anti-inflammatory drugs (e.g. celecoxib) reduce prostagladin
synthesis and cause side effects such as gastrointestinal ulcerations and renal complications. The aim of
this study was to formulate celecoxib entrapped poly lactide-co-glycolide based nanoparticles through a
solvent evaporation process using didodecyldimethylammonium bromide or poly vinyl alcohol as
stabilizer. Nanoparticles were characterized for zeta potential, particle size, entrapment efficiency, and
morphology. Effects of stabilizer concentration (0.1, 0.25, 0.5, and 1 % w/v), drug amount (5, 10, 15,
and 20 mg), and emulsifier (lecithin) on nanoparticle characterization were examined for formula
optimization. The use of 0.1%, 0.25% and 0.5% w/v didodecyldimethylammonium bromide resulted in
more than a 5-fold increase in zeta potential and more than a 2 fold increase in entrapment efficiency
with a reduction in particle size over 35%, when compared to stabilizer free formulation. Nanoparticle
formulations were also highly influenced by emulsifier and drug amount. Using 0.25% w/v
didodecyldimethylammonium bromide NP formulations, peak zeta potential was achieved using 15 mg
celecoxib with emulsifier (17.15 ± 0.36 mV) and 20 mg celecoxib without emulsifier (25.00 ± 0.18 mV).
Peak NP size reduction and entrapment efficiency was achieved using 5 mg celecoxib formulations with
(70.87 ± 1.24 nm and 95.55 ± 0.66%, respectively) and without (92.97 ± 0.51 nm and 95.93 ± 0.27%,
respectively) emulsifier. In conclusion, formulations using 5 mg celecoxib with 0.25% w/v
didodecyldimethylammonium bromide concentrations produced nanoparticles exhibiting enhanced size
reduction and entrapment efficiency. Furthermore, emulsifier free formulations demonstrated improved
zeta potential when compared to formulations containing emulsifier (p < 0.01). Therefore, our results
suggest the use of emulsifier free, 5 mg celecoxib drug formulations containing 0.25% w/v
didodecyldimethylammonium bromide for production of polymeric NPs that demonstrate enhanced zeta
potential, small particle size, and high entrapment efficiency.

Keywords: NSAIDs; Celecoxib; Formulation; PLGA; Nanoparticles; DMAB; PVA
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are well established for the treatment of pain and
inflammation. They function by acting on the cyclo-oxygenase (COX) family of enzymes and inhibiting
the conversion of arachidonic acid to prostaglandins and thromboxanes [1-4]. The COX enzyme exists
as at least two different isozymes, COX-1 and COX-2. The COX-1 enzyme is constitutively expressed
in most tissue and functions to regulate hemodynamics and maintain gut integrity. COX-2 is an
inducible enzyme found primarily at sites of inflammation that mediates fever and pain [5-7]. COX-2
has been found to be constitutively expressed in certain tissue such as the kidneys, the reproductive tract,
and gastric mucosa [2,8-11]. Traditionally, NSAIDs function by inhibiting both COX-1 and COX-2
isozymes and provide analgesic and anti-inflammatory benefits. These benefits are thought to arise
primarily from the inhibition of COX-2, while the adverse effects (e.g. ulceration) were thought to occur
from over inhibition of COX-1 [12-14]. As a result, COX-2-selective inhibitors (COXIBs) were
developed to provide analgesic and anti-inflammatory benefits, while minimizing the gastrointestinal
adverse side effects associated with traditional NSAID use [1,12].
Celecoxib (CEL) is a COXIB used in the treatment of pain and inflammation [13-15]. Evidence suggests
that CEL use effectively reduces clinical gastrointestinal events in comparison to other NSAIDs, making
it one of the most commonly prescribed COX-2 specific inhibitors [16-18]. Despite the general safety of
CEL in regards to gastrointestinal tolerability, its use has been associated with the development of
several adverse side effects including cardiovascular events, and renal toxicity [18,19]. Many CEL
delivery systems designed to help reduce and alleviate the formation of CEL associated side effects have
been developed [20-23]. Studies utilizing nanoparticle (NP) formulations have shown promising results
in overcoming high dose oral administration of CEL [22,24-26]. One study showed enhanced drug
retention at the site of action following intra-articular injection of small lipid nanoparticle formulated
CEL in the treatment of joint pain [27]. Another study showed enhanced anti-inflammatory effects of
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CEL utilizing NP formulated transdermal drug delivery [28]. A third study showed enhanced inhibition
of tumor growth with a reduction in side effects using hydroxyapatite-chitosan nanocomposited CEL in
the treatment of colon cancer [29].
Polymer based NPs are commonly used to improve drug bioavailability and/or reduce drug
associated side effects [30]. Poly lactide-co-glycolide (PLGA) is a polymer that has been
commercialized for a variety of drug delivery systems and is frequently used in the design of
biocompatible NPs [31]. PLGA is approved by the Food and Drug Administration as a biodegradable
polymer that degrades to the nontoxic tricarboxylic acid cycle intermediates, lactic acid and glycolic
acid [31-33]. Use of PLGA based NPs for enhanced delivery of CEL has been met with a variety of
different results. [20,21]. However, known NP stabilizers such as didodecyldimethylammonium bromide
(DMAB) and poly vinyl alcohol (PVA) have yet to be used in the development of CEL loaded PLGANPs.
Previous studies have shown effective use of DMAB and PVA for formulation of small, highly
entrapped NPs [34,35]. The aim of this study was to characterize and optimize CEL loaded PLGA-NPs
by examining the influence of varying DMAB and PVA concentrations on NP characterstics. The effect
of drug amount and emulsifier (lecithin) on zeta potential, particle size, entrapment efficiency, and
morphology was also examined.

Materials and methods
1.1. Materials

DMAB, PVA (MW 89,000 – 98,000 Da, 99.9+% hydrolyzed), PLGA (50:50 copolymer compositions;
MW 30,000 – 60,000 Da), and lecithin (99% phosphatidylcholine) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). CEL base powder was obtained from Biovision Incorporated (Milpitus, CA,
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USA). Acetone, ethyl acetate, and high-performance liquid chromatography (HPLC)-grade water were
purchased from Fischer Scientific Laboratory (Fair Lawn, NJ, USA).

1.2. Preparation of CEL loaded PLGA-NPs

Formulation of NPs was carried out using a previously described solvent evaporation technique [34,36].
CEL-loaded NPs were formulated by dissolving 20 mg of CEL and 50 mg PLGA into 3 mL of ethyl
acetate. The solution was stirred for 30 minutes at 750 rpm. Afterwards, 30 mg of lecithin was added to
the organic solution followed by addition of 500 µL acetone as co-solvent. A varying range of DMAB or
PVA concentrations (0.1%, 0.25%, 0.5%, and 1% w/v) was dissolved in 6 mL of HPLC grade water.
Organic phase was then added to aqueous phase in a drop wise manner under moderate stirring followed
by sonication for 5 minutes at 20 KHz. After sonication, solutions were stirred at 750 rpm for 1 hour to
evaporate organic phase. Emulsions were then centrifuged at 12,000 rpm followed by separation of
supernatant from precipitants. Additional NP formulations for optimization studies were carried out with
0.25% w/v DMAB concentration. Using the previously described process, emulsifier free CEL loaded
PLGA-NPs were formulated with the exclusion of lecithin, while NP preparation looking at effects of
drug amount was carried out using various amounts of CEL (5, 10, 15, and 20 mg).
1.3. Particle size and zeta potential

Intensity weighted mean particle size (diameter) was measured in triplicate by dynamic light scattering
using a NICOMP particle sizer (Particle Sizing Systems, Port Richy, FL, USA). Zeta potential was
estimated on the basis of electrophoretic mobility under an electrical field.
1.4. Drug entrapment

To measure drug entrapment efficiency 100 µL NP solution was added to 300 µL acetonitrile and vortex
mixed for 30 seconds. Afterwhich, 100 µL of drug loaded NP solution was analyzied under ultraviolet–
visible spectroscopy (Eppendorf Biophotometer, Hauppauge, NY, USA) at 260 nm using empty NPs
solutions as blank. A standard calibration curve (50,000 – 2,000,000 ng/mL) was constructed using
79

titrated dilutions of CEL stock solution dissolved in acetonitrile. Drug entrapment efficiency (EE) was
calculated using the following equation:
Entrapment efficiency = (Amount of CEL entrapped within nanoparticles/Total amount of CEL used for
formulation) X 100
1.5. Morphology

Transmission electron microscopy (TEM) (Tecnai Philips Transmission Electron Microscope; FEI,
Hillsboro, Oregon, USA) was used for evaluation of CEL loaded PLGA-NP shape and surface
morphology. NP emulsions were vortex mixed and 2 µL of suspension was placed on a 200 mesh copper
grid covered with Formvar film (Electron Microscopy Sciences, Hatfield, Pennsylvania). Samples were
air dried for 1 hour then examined at 80 kV.
1.6. Stability of CEL loaded PLGA-NPs

CEL loaded PLGA-NP emulsions (5 mL) formulated at various drug amounts (5, 10, 15, and 20 mg)
with or without emulsifier (0.25% w/v DMAB) were stored at 4 °C for a period of 16 weeks. After 16
weeks samples were removed from storage and analyzed for particle size, zeta potential, and drug
entrapment efficiency. Particle characteristics were evaluated as previously described.
1.7. Data analysis

All experiments were performed in triplicate. NP characteristic data is represented as mean ± standard
deviation (SD). A Student’s t-test was used for comparison of two groups.

Results and discussion
1.8. Effect of stabilizer concentration on NP characteristics

CEL encapsulated PLGA-NPs were developed using lecithin as an emulsifier with DMAB or PVA
(Table 4.1). The use of DMAB or PVA resulted in formation of CEL loaded PLGA-NPs with surface
characteristics that displayed positive and negative charges, respectively. Because of the cationic
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properties of DMAB [37-39], NPs formulated with inclusion of DMAB showed highly positive surface
charges (Fig. 4.1A).

DMAB formulated CEL loaded NPs reached a peak zeta potential of 20.03 ± 0.84 mV at 0.5% w/v
concentration. The anionic characteristics of PVA lead to the formation of NPs with slightly negative
surface charges (Fig. 4.1B). PVA formulated NPs reached a peak zeta potential of -6.09 ± 1.39 mV with
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0.25% w/v concentration.

When comparing zeta potential as a measure of stability, all CEL-NP formulations containing
DMAB or PVA showed significant alterations in NP system stability compared to stabilizer free
formulations (plain formulation) (Fig. 4.1A and Fig. 4.1B). These results are indicative of altered NP
characteristics as a result of adsorption or inclusion of DMAB and PVA onto or within the NP polymer
shell. The inclusion of cationic and anionic DMAB (Fig. 4.1A) or PVA (Fig. 4.1B) on NP surfaces can
effectively alter overall NP charge, in turn, effecting overall system stability [39-41].
In comparison to plain formulation, a significant reduction in particle size was seen in formulations
incorporating 0.1%, 0.25%, and 0.5% DMAB (Fig. 4.2).
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Particle size was significantly increased in 1% DMAB concentrations when compared to plain
formulation. The largest reduction in particle size was achieved using 0.25% DMAB concentration
(99.97 ± 3.27 nm) (p < 0.01). High concentrations of DMAB have been shown to increase solution
viscosity, resulting in a direct increase in particle size [42], which may explain the significant rise in
particle size noticed with CEL-NPs formulated using larger amounts of stabilizer. Furthermore, DMAB
can act as a solubilizing agent for known hydrophobic compounds [36]. It is possible that lower DMAB
concentrations may act to effectively reduce drug crystallization, further reducing NP size, which may
explain NP size reductions seen in our study with lower DMAB concentrations (Fig. 4.2). Conversely, a
significant increase in CEL solubility brought forth by higher DMAB content could function to increase
NP drug loading capacitance and increase particle size by means of expanding NP drug content within
the polymer shell.
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Formulations using 0.1% w/v PVA did not demonstrate any significant difference in particle size when
compared to plain formulation (p > 0.77). Particle size measurements of 0.25%, 0.5% and 1% PVA
formulations were not detectable by our NICOMP particle sizer due to reduced entrapment efficiency
and total drug concentrations in PVA based NP solution.
The amount (1.99 ± 0.01 mg) and percent (9.94 ± 0.01%) of CEL entrapped in formulations without
stabilizer were compared to DMAB and PVA based formulations (Table 4.2). All stabilizer based
formulations demonstrated significant changes in entrapment efficiency when compared to plain
formulation (Table 4.2) (P < 0.01).

All DMAB formulations and 0.1% PVA formulation exhibited significant increases in the level of CEL
entrapment with a maximum percent entrapment of 61.07 ± 0.06% reached with 1% DMAB
formulation. All PVA concentrations above 0.1% w/v underwent a significant reduction in drug
entrapment (Table 4.2). The reduction in drug entrapment can be explained by elucidation of PVA
properties. PVA is a highly hydrophilic stabilizer, which can result in reduced NP stability in aqueous
solutions [43]. As PVA concentrations increase, the hydrophilic nature of the NP system increases. The
increased inclusion of PVA into the NP polymer shell could increase hydrophilic properties leading to
NP solubilization in the aqueous medium following organic phase evaporation. The increased
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hydrophilic properties of PVA-NP systems could reduce entrapment and drug solubility leading to an
increased loss of drug in solution precipitant following centrifugation.
In this study, DMAB was shown to effectively increase zeta potential, reduce particle size, and facilitate
drug entrapment when compared to PVA based formulations. As such, DMAB based NP morphology
was visualized and confirmed under transmission electron microscopy (TEM) (Fig. S1) with further
variable analysis carried out using DMAB formulations.
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0.28.

Analysis of NP characteristics in absence of emulsifier

To analyze effect of emulsifier on CEL loaded NP characteristics, formulations containing 0.1%, 0.25%,
0.5%, and 1% w/v DMAB without lecithin were developed, characterized and compared to previously
observed characteristics of NP formulations with lecithin (Fig. 4.3).

NP
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visual identification of emulsifier free formulations was performed via TEM analysis (Fig. S2).

When
compared to emulsifier based formulations, absence of emulsifier resulted in a significant increase of
zeta potential in formulations using 0.25%, 0.5%, and 1% stabilizer concentrations (Fig. 4.3A) (P <
0.01). These findings indicate that the use of an emulsifier may function to reduce overall particle
repulsion and system stability. The cationic property of DMAB has become increasingly popular for
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development of positively charged NPs [44]. In emulsifier free formulations, we found that rising zeta
potential was associated with increased DMAB concentration. These results can be indicative of
enhanced DMAB inclusion into the NP polymer shell. Furthermore, lecithin contains low concentrations
of phosphatidic acid. The presence of phosphatidic acid can impart negatively charged, anionic
characteristics during inclusion into NP formulations [45]. As such, the anionic properties of lecithin can
act to reduce polymer surface charge and effectively mask the cationic charge associated with DMAB
inclusion, which would explain the findings of reduced particle charge seen in emulsifier based NP
formulations.
In emulsifier free formulations particle size increased with increasing stabilizer concentrations, with
peak particle size reaching micron levels at 0.5% and 1% DMAB concentration (972.93 ± 547.71 nm
and 4849.77 ± 313.75 nm, respectively) (Fig. 4.3B). These results indicate that lecithin effectively
functions to reduce interfacial tension between organic and aqueous phases. In solvent evaporation
processes, when organic phase is added to aqueous phase in a drop wise manner, the resultant organic
droplets are stabilized by polymers formed at solute interfaces [45]. The type of polymer, surfactant, or
emulsifier used can act to alter interfacial tensions between the organic droplets and the aqueous
solution. After placement of organic phase into aqueous phase, interfacial spreading occurs as a result of
diffusion between solvents, providing energy for NP formation [45]. NP size is dependent on rate of
diffusion and diffusion is dependent on changes in the interfacial tension between organic and aqueous
phases. Lower interfacial tension equates to smaller NP size properties [45-48]. The addition of
compounds such as lecithin act to effectively change interfacial tension which can have altering effects
on particle size and NP formation [48,49]. Changes in organic and aqueous phase interface alters the rate
of solvent diffusion, as lecithin favors a higher organic phase to aqueous phase interface resulting in
reduced particle size [46] as seen in our study.
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Peak drug entrapment was seen at DMAB concentrations of 1% for formulations without emulsifier
(82.91 ± 0.67%) (Fig. 4.3C). In relations to 1% DMAB formulation carried out with emulsifier, these
results equate to an almost 22% increase in NP drug loading (P < 0.01). In theory, inclusion of lecithin
could act to offset surface tension allowing for fast organic phase diffusion into the aqueous phase [50].
The alteration in interfacial tension could also function to reduce barrier transport of drug outside of the
organic phase during solvent diffusion. Inclusion of lecithin into the polymeric shell with increasing
concentrations of DMAB resulted in a net reduction in drug entrapment compared to its emulsifier free
counterpart. Much like lecithin, DMAB can form micelle aggregates that function through hydrophobic
interactions of DMAB with the hydrophobic core of the NP [34]. The interactions of the hydrophobic
portion of the stabilizer can function to solubilize the hydrophobic drug entrapped within the NP core
[36]. It is possible that as concentration of both DMAB and lecithin increased in formulations, the net
rise in hydrophobic interaction resulted in increased NP and CEL solubility leading to drug leakage and
reduced drug entrapment. Similar results were obtained by Thakkar et al. when using Span-85 as an
emulsifying agent during the development of CEL microspheres [51]. In the study, it was found that
addition of emulsifier with high concentrations of stabilizer (1% w/v) enhanced CEL solubility and
dissolution, which led to a reduction in both particle size and drug entrapment.
Previously, our lab completed formulation of diclofenac (a non-selective NSAID) loaded PLGA-NPs
using DMAB and PVA [34]. With no change in drug amount (45 mg) or use of emulsifier, diclofenac
loaded PLGA-NPs with DMAB or PVA exhibited negative surface charges and a peak entrapment
efficiency as high as 80.21 ± 1.21%. The negative NP surface charge associated with diclofenac NP
formulations using DMAB contrast with the highly positive surface charge of DMAB formulated CEL
loaded NPs found in this study. When using diclofenac, PVA formulated NPs showed smaller negative
surface charges, similar to the negative surface charge characteristics associated with our PVA
formulated CEL-NP formulation. In physiological conditions, diclofenac is a negatively charged
89

molecule which may play a role in the development of negatively charged NPs during formulation with
DMAB [52]. Conversely, at physiological pH, CEL presents as a neutrally charged molecule [53] that,
when formulated with cationic DMAB, resulted in formation of positively charged NPs. Particle size
analysis showed a similar pattern when comparing CEL formulation results with that of diclofenac.
Diclofenac NP formulation showed a maximum increase of NP size (189.9 ± 4.9 nm) using 1% w/v
DMAB. Similarly, results of our CEL formulation study demonstrated maximum NP size with 1% w/v
DMAB concentration (Fig. 4.3B). Measurements of entrapment efficiency showed opposite effects. For
diclofenac NPs, a linear reduction in total entrapment efficiency was seen with regards to increasing
DMAB concentrations with the lowest amount of diclofenac entrapment occurring with 1% w/v DMAB.
Conversely, maximum CEL loading seen within this study was observed at 1% DMAB, which when
compared to the highly polarizable diclofenac [54], supports the theory that higher concentrations of
DMAB may increase solubility of lipophilic drugs such as CEL, in turn leading to increases in particle
size and drug entrapment [42].
0.28.

Effect of drug amount on NP characteristics

To study the effect of drug amount on NP characteristics, formulations consisting of 0.25% DMAB
concentrations were chosen based on their sufficient size and general representation of drug entrapment
and zeta potential. In conjunction with previously formulated NP systems using 20 mg CEL, new NPs
with or without emulsifier were formulated with increasing amounts (5, 10, and 15 mg) of CEL (Table
4.3).
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Morphological characterization of NPs formulated with (Fig. 4.4) and without (Fig. 4.5) emulsifier at
various drug amounts showed spherical shape and size similar to what was noticed in previous
formulation studies [24,25,55-59]. All NP formulations without emulsifier displayed significantly higher
zeta potential compared to formulations with emulsifier (Fig. 4.6A) (p < 0.01). Maximum zeta potential
was reached in formulations of 20 mg CEL without emulsifier (25.00 ± 0.18 mV). Formulations with
emulsifier reached peak zeta potential using 15 mg CEL (17.15 ± 0.36 mV). These results further
indicate that use of emulsifiers such as lecithin, can function to mask surface charge of the incorporated
stabilizer thereby reducing overall cationic charge associated with DMAB formulated NPs [45].
Peak size reduction and entrapment efficiency for formulations with (70.87 ± 1.24 nm and 95.55 ±
0.66%, respectively) and without (92.97 ± 0.53 nm and 95.93 ± 0.27%, respectively) emulsifier was
achieved using 5 mg drug amounts (Fig. 4.6B and Fig. 4.6C, respectively). These results indicate an
important role for drug solubility on the characterization of CEL loaded NPs.
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CEL belongs to the biopharmaceutical classification system class II drug exhibiting poor aqueous
solubility [60-62]. During formulation, several techniques such as size reduction, use of emulsifier, or
surfactants can be applied to help increase the degree of drug solubility in aqueous media [63]. In
93

applications towards NP production, several of these techniques are often applied in order to increase
drug solubility and prevent drug precipitation outside of the NP shell. In this study, stabilizers and an
emulsifier were used to measure effects on particle characteristics through means of increased solubility.
The use of drug amount was also analyzed as a measurement of solubility effects on zeta potential,
particle size, and drug entrapment. In an effort to optimize drug entrapment, drug amounts were titrated
to measure extent of effects on NP encapsulation. The solubility of a drug is related to surface area and
volume ratios [63]. In particle size reduction, surface area is increased and allows greater interactions
with the solvent which causes an increase in solubility. In conjunction with particle size reduction via
sonication, reductions in drug amount allows further enhancement in surface area to volume ratio. We
found that when drug amount was decreased in CEL-NP formulations, entrapment efficiency was able to
achieve over 95% loading capacitance (Fig. 4.6C). This success indicates the importance of drug amount
in conjunction with size reduction for the prevention of drug precipitation and enhancement of drug
entrapment efficiency during NP formulations.
Interestingly, in this study it was found that as drug amount increased to 20 mg, total entrapment of
CEL increased in formulations with emulsifier while amounts of 15 mg and 10 mg CEL displayed
increasing total drug entrapment in regards to emulsifier free formulation (Fig. 4.6C). It is possible that
higher concentrations of CEL undergoes enhanced solubilization in the presence of emulsifier, enabling
a larger degree of drug entrapment in the presence of higher drug amounts. Furthermore, lecithin is a
non-ionic emulsifier known to impart steric stabilizing effects in colloidal systems, preventing particle
collision and reducing drug leakage [64,65]. It is possible that as drug amounts increase, lecithin
functions to increase drug solubility, stabilize NP formation, and reduce drug leakage leading to an
increase in drug entrapment. The observation that larger drug amounts undergo increased NP entrapment
in the presence of lecithin may support the use of emulsifiers during NP production of high, lipophilic
drug concentrations.
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3.4. Stability of CEL loaded PLGA-NPs

To avoid particle aggregation and coalescence, it is recommended to store PLGA-NP systems at 4 °C
[66]. Therefore, to analyze stability of PLGA-NP systems, emulsions of varying drug amounts with or
without emulsifier were kept at 4 °C for a period of 16 weeks then characterized to determine storage
effects on zeta potential, particle size, and drug entrapment efficiency.
Results showed that zeta potential, particle size, and entrapment efficiency were at or below initial
reported NP characterization measurements (Fig. 4.7 and Fig. 4.8).
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All peak characteristic measurements after 16 weeks of cold storage was noticed in formulations that
included emulsifier (Fig. 4.7). When compared to our initial formulations (Fig. 4.6), zeta potential was
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reduced across all formulations (p < 0.05), with a peak zeta potential seen in formulations using 10 mg
drug amounts with emulsifier (5.92 ± 0.98 mV) (Fig. 4.7A). When analyzing particle diameter, a peak
reduction was seen in 10 mg formulations with emulsifier (63.23 ± 3.33 nm). Furthermore, when
compared to initial characteristic measurements, significant particle size reductions were seen in 10 mg
and 20 mg CEL formulations with emulsifier (Fig. 4.7B) (p < 0.01), as well as 5 mg and 15 mg
formulations without emulsifier (Fig. 4.8B) (p < 0.01). All formulations showed a significant reduction
(p < 0.01) in entrapment efficiency with the highest level of entrapment maintained in 5 mg formulation
with emulsifier (79.58 ± 0.611%) (Fig. 4.7C). These results indicate the possible role emulsifying agents
may have on maintenance of NP stability. The reduction of zeta potential observed in all formulations
could be a result of possible DMAB dissociation from the NP shell after 16 weeks. Loss of DMAB
would lead to reduced particle charge, net repulsion, and stability resulting in increased drug leakage,
particle size reduction, and reduced entrapment efficiency [67]. Furthermore, the emulsifier in our
formulation may be exerting unknown effects on drug permeation and NP aggregation, allowing for
enhanced time-dependent stability of PLGA-NPs formulated with lecithin [68].

Conclusion
In this study, we performed a solvent evaporation technique to developed and characterize CEL loaded
PLGA-NPs using varying concentrations of DMAB or PVA as stabilizer. NPs were examined and
characterized based on zeta potential, size, drug entrapment efficiency, and morphology. The results of
this study showed that the use of DMAB as stabilizer led to the development of NPs that displayed
sufficient size and stability with moderate increases in drug entrapment when compared to plain
formulation. Of the two stabilizers, DMAB proved to be highly efficient in developing well
characterized CEL loaded PLGA based NPs, whereas PVA based formulations failed to reach optimum
parameters in NP development. Variables such as emulsifier and drug amount were also analyzed to
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further optimize NP formulations. When formulations were carried out in the presence of emulsifier a
reduction in zeta potential was noted. Emulsifier based formulations displayed reduced surface charge as
a consequence of lecithin induced anionic interactions and masking of cationic DMAB properties,
indicating that in the presence of DMAB based formulations, emulsifiers such as lecithin may act to
reduce NP stability and formula optimization. Additional formula evaluation showed that reduction in
drug amount was effective at reducing particle size and enhancing drug entrapment efficiency, further
elucidating the role of drug solubility and the importance of increasing surface area to solvent
interactions for effective development of CEL loaded NPs. Interestingly, while use of emulsifier resulted
in reduced zeta potential and system stability, time-dependent stability testing which looked at zeta
potential, size, and entrapment efficiency after 16 weeks cold storage showed peak particle
characteristics in formulations with emulsifier. These results may indicate that while emulsifiers such as
lecithin function to reduce overall particle charge during formulation, they could function to prolong NP
system stability over an extended period of time. However, further testing is needed to determine the
extent of emulsifier effects on CEL loaded PLGA-NP stability. Overall, results of our study indicate
formulation of PLGA-NPs using 0.25% w/v DMAB and 5 mg CEL amounts without emulsifier for
creation of highly entrapped, stable NPs of a sufficient size that could function to enhance the
application of orally delivered CEL and provide a potential effective dosage form for CEL
administration.
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Supporting Information
Figure S1. TEM images of emulsifier based formulation illustrating morphology of A) 0.1% w/v
DMAB formulated NPs, B) 0.25% w/v DMAB formulated NPs, C) 0.5% w/v DMAB formulated NPs
and D) 1% w/v DMAB formulated NPs.
Figure S2. TEM images of emulsifier free formulations illustrating morphology of A) 0.1% w/v DMAB
formulated NPs, B) 0.25% w/v DMAB formulated NPs, C) 0.5% w/v DMAB formulated NPs and D)
1% w/v DMAB formulated NPs.
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Figure Legends
Figure 4.1. Zeta potential measurements of A) DMAB and B) PVA formulated NPs of celecoxib.
Values are expressed as mean ± SD, n = 3. *p < 0.05, significantly different from plain formulation.
Figure 4.2. Particle size analysis of increasing concentrations of DMAB compared to formulation
without stabilizer (plain formulation). Values are expressed as mean ± SD, n = 3. *p< 0.05, significantly
different from plain formulation.
Figure 4.3. Nanoparticle characteristic comparison of A) zeta potential, B) particle size, and C)
entrapment efficiency of initial emulsifier based DMAB formulations with emulsifier free DMAB
formulations. Values are expressed as mean ± SD, n = 3. *p < 0.05, significantly different from initial
formulations.
Figure 4.4. TEM images illustrating morphology of 0.25% w/v DMAB NP formulations with emulsifier
at A) 5 mg drug amount, B) 10 mg drug amount, C) 15 mg drug amount, and D) 20 mg drug amount.
Figure 4.5. TEM images illustrating morphology of 0.25% w/v DMAB NP formulations without
emulsifier at A) 5 mg drug amount, B) 10 mg drug amount, C) 15 mg drug amount, and D) 20 mg drug
amount
Figure 4.6. The effect of varying drug amounts on A) zeta potential, B) NP size, and C) entrapment
efficiency. Values are expressed as mean ± SD, n = 3. *p < 0.05, significantly different from
formulations with emulsifier.
Figure 4.7. Nanoparticle characteristic comparison of A) zeta potential, B) particle size, and C)
entrapment efficiency of initial emulsifier based formulations with those observed following 16 weeks
cold storage at 4 °C. Values are expressed as mean ± SD, n = 3. *p < 0.05, significantly different from
initial formulations.
Figure 4.8. Nanoparticle characteristic comparison of A) zeta potential, B) particle size, and C)
entrapment efficiency of initial emulsifier free formulations with those observed following 16 weeks
cold storage at 4 °C. Values are expressed as mean ± SD, n = 3. *p < 0.05, significantly different from
initial formulations.
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CHAPTER 5
SUMMARY
The purpose of this study was to formulate, develop and optimize a new NP based drug delivery
system that could be used to enhance and/or mitigate effects of the nonsteroidal anti-inflammatory drugs
(NSAIDs) diclofenac or celecoxib (Cooper and Harirforoosh 2014; Cooper and Harirforoosh 2014). A
solvent-evaporation technique was used to developed and characterize diclofenac or celecoxib loaded
polymeric NPs using DMAB or PVA as stabilizer. NPs were characterized based on size, stability,
morphology and percent of drug entrapped. For all active pharmaceutical ingredients examined in this
study, the use of DMAB as stabilizer resulted in the development of NP systems that demonstrated
sufficient size and stability characteristics while also showing moderate increases in drug entrapment
when compared to plain formulation. Optimization experiments were designed and carried out for each
drug as well. Effects of centrifugal force, stabilizer concentration, emulsifier and total drug amounts on
formulation parameters such as zeta potential, drug entrapment, and particle size were examined.
During formulation studies, it was found that PLGA based NPs using DMAB as stabilizer,
resulted in formation of highly stable NPs for both diclofenac and celecoxib. In diclofenac
formulation, PLGA based NPs showed the lowest particle size (108 ± 2.1 nm) and highest zeta
potential (-27.71 ± 0.6 mV) at 0.1 and 0.25% DMAB respectively, when centrifuged at 12,000 rpm.
Peak drug entrapment reached 77.3 ± 3.5% (20). Results of diclofenac and PVA based NP formulation
showed the smallest particle size (92.4 ± 7.6 nm) and highest zeta potential (11.14 ± 0.5 mV) at 0.25%
and 1% w/v, respectively, after centrifugation at 12,000 rpm. Diclofenac NP formulations utilizing PVA
stabilizer reached an entrapment efficiency of 80.2 ± 1.2%. Over all, zeta potential levels were
dramatically lower in PVA based formulations then DMAB based formulations. The lower level of zeta
potential seen in PVA formulas indicates a high degree of system instability and particle agglomeration
(Cooper, D.L. 2014). Hindrance of particle repulsion brought forth by the reduced surface charge would
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allow cohesion and aggregation of NP presented within the system. This aggregation would negate the
benefits of nanosizing and lead to leaching of the drug out of the NP shell and/or falling out of solution.
This finding alone supports the use of DMAB as the primary stabilizer to be used during diclofenac NP
formulation.
In optimization techniques it was found that both emulsifier and drug amount could affect NP
characteristics during formulation of celecoxib loaded NPs (Cooper and Harirforoosh 2014). For these
formulations, peak zeta potential was achieved using 15 mg celecoxib with emulsifier (17.15 ± 0.36 mV)
and 20 mg celecoxib without emulsifier (25.00 ± 0.18 mV). The largest particle size reduction and
entrapment efficiency was achieved using 5 mg celecoxib formulations with (70.87 ± 1.24 nm and 95.55
± 0.66%, respectively) and without (92.97 ± 0.51 nm and 95.93 ± 0.27%, respectively) emulsifier. It is
important to note that during celecoxib NP formula optimization, reaching entrapment efficiency at or
above 50%, while maintaining favorable characteristic profiles for both zeta potential and particle size,
was difficult to achieve. Initial formulations that looked at effects of stabilizer concentration and
emulsifier on NP characteristics showed entrapment percent’s over 50% only when total stabilizer
concentrations reached 0.5 – 1%. Unfortunately, although entrapment efficiency reached adequate
levels, higher amounts of stabilizer, both with and without emulsifier, demonstrated particle sizes on a
micron scale. When dealing with nano based formulations, these findings are unacceptable. It was only
when optimization techniques were employed that altered the actual amount of drug used, were
favorable characteristics seen among the categories of both zeta potential and particle size as well as
drug entrapment. Effects of drug amount on formulation characteristics were analyzed by formulating
celecoxib based NP systems using 5 mg, 10 mg, 15 mg or 20 mg drug amounts. In this study, when
lower amounts of drug was used (5 mg) entrapment efficiency reached a peak level of over 95% with or
without the use of an emulsifier. Do to the extremely high levels of entrapment seen, a conclusion could
be drawn that formulations performed with 5 mg drug amounts gave the best celecoxib loaded NPs.
107

Furthermore, this study shows that formulas utilizing 5 mg drug amounts without the use of a secondary
emulsifier led to formation of sufficiently small NPs with a high degree of stability. These findings
support the conclusion that formulation of celecoxib NPs using lower drug amounts without emulsifier
results in optimal NP system development.
Overall, results of this study demonstrated successful formulation of diclofenac and celecoxib
loaded polymeric NPs (Cooper and Harirforoosh 2014; Cooper and Harirforoosh 2014). The findings
presented here may indicate a novel delivery method that could function to decrease or eliminated drug
induced adverse side effects seen in the clinical settings (Marimuthu et al 2013; Tai et al 2013; Cooper
and Harirforoosh 2014; Cooper and Harirforoosh 2014). However, while the present research is
promising, further research is needed to elucidate the overall effect of NP drug delivery on these select
pharmacotherapeutics.
Despite successful formulation techniques presented here, extensive research is still needed to
uncover the exact affect these new formulations will have on overall drug function and characteristics. In
depth research and examinations, including in vivo studies should be performed to measure the extent of
NP effects on maintenance of drug efficacy and the formation of adverse events associated with acute
and chronic drug exposure. For NSAID formulated NPs, in vivo pharmacokinetic and pharmacodynamic
studies should be carried out to assess and examine drug dosing and formula effects on systemic
exposure, onset of adverse effects and maintenance of overall drug efficacy. Due to known adverse
effects of NSAIDs in regards to gastrointestinal disturbances and renal complications, the extent of drug
induced NSAID NP effects to be analyzed should include analysis of electrolyte concentrations before
and after regimen initiation, and gastrointestinal histological examination. Furthermore, biomarkers such
as blood urea nitrogen and urinary kidney injury molecule 1, as a measure of the extent of drug induced
renal stress, should also be examined. Examination of effects on inflammation and prostaglandin
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expression as a measure of drug efficacy could be carried out utilizing ELISA assays and biomarker
analysis of cyclo-oxygenase (COX), myeloperoxidase, and prostaglandin E2 levels.
The experiments outlined above are designed to evaluate the effectiveness of these polymer
encapsulate drugs in achieving enhanced systemic absorption following oral dosing. Utilization of in
vivo data will serve as a strong indicator in regards to formulation effectiveness at achieving adequate
and sustained plasma drug concentrations and further elucidate effects of these formulations on
associated adverse drug events and the maintenance or enhancement of overall drug efficacy.
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